CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | imidazole antifungal drug |
|
Accession: | CHEBI:87069
|
browse the term
|
Definition: | Any imidazole antifungal agent that has been used for the treatment of fungal infections in humans or animals. |
Synonyms: | related_synonym: | imidazole antifungal drugs |
|
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
bifonazole results in decreased activity of CYP19A1 protein |
CTD |
PMID:15554355 PMID:24496634 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
bifonazole results in decreased activity of CYP3A4 protein |
CTD |
PMID:15135088 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity |
ISO |
bifonazole results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
butoconazole results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
butoconazole results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
climbazole results in increased expression of CYP2B1 mRNA; climbazole results in increased expression of CYP2B1 protein |
CTD |
PMID:11552297 PMID:11824557 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
EXP |
climbazole results in increased expression of CYP3A2 protein |
CTD |
PMID:11552297 PMID:11824557 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
climbazole results in increased expression of CYP4A1 protein |
CTD |
PMID:11552297 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Clotrimazole results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects binding multiple interactions increases expression |
ISO |
Clotrimazole binds to ABCB1 protein Clotrimazole inhibits the reaction [ABCB1A protein results in increased secretion of fluorexon] Clotrimazole results in increased expression of ABCB1 protein Clotrimazole inhibits the reaction [ABCB1 protein results in increased export of Doxorubicin]; Clotrimazole inhibits the reaction [ABCB1 protein results in increased secretion of fluorexon]; Clotrimazole inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine] |
CTD |
PMID:8632764 PMID:8917702 PMID:12235267 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Clotrimazole results in increased expression of ABCC2 mRNA; Clotrimazole results in increased expression of ABCC2 protein |
CTD |
PMID:11836020 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
ISO |
MAPK14 promotes the reaction [Clotrimazole results in increased expression of ABCC3 mRNA]; SB 203580 inhibits the reaction [Clotrimazole results in increased expression of ABCC3 mRNA] |
CTD |
PMID:27507784 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acp2 |
acid phosphatase 2, lysosomal |
increases expression |
EXP |
Clotrimazole results in increased expression of ACP2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:77,175,022...77,185,180
Ensembl chr 3:77,175,895...77,185,680
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ADAM22 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962
|
|
G |
Adamts12 |
ADAM metallopeptidase with thrombospondin type 1 motif, 12 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ADAMTS12 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:60,032,873...60,327,629
Ensembl chr 2:60,032,873...60,327,629
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
increases expression |
EXP |
Clotrimazole results in increased expression of ADAMTS7 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:90,704,727...90,744,333
Ensembl chr 8:90,704,727...90,744,328
|
|
G |
Adamtsl5 |
ADAMTS-like 5 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ADAMTSL5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 7:9,362,623...9,371,248
Ensembl chr 7:9,363,237...9,370,285
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ADAR mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:175,138,391...175,178,280
Ensembl chr 2:175,138,403...175,178,282
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases activity |
ISO |
Clotrimazole results in decreased activity of ADCY9 protein |
CTD |
PMID:30607468 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Adora2a |
adenosine A2a receptor |
increases expression |
EXP |
Clotrimazole results in increased expression of ADORA2A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Aebp1 |
AE binding protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of AEBP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877
|
|
G |
Agfg1 |
ArfGAP with FG repeats 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of AGFG1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:84,124,845...84,182,615
Ensembl chr 9:84,125,120...84,178,128
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
ISO |
Clotrimazole results in increased activity of AHR protein |
CTD |
PMID:26187274 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak6 |
adenylate kinase 6 |
increases expression |
EXP |
Clotrimazole results in increased expression of AK6 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:31,794,316...31,806,375
Ensembl chr 2:31,794,519...31,806,371 Ensembl chr20:31,794,519...31,806,371
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
increases expression |
EXP |
Clotrimazole results in increased expression of ALDH9A1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
affects localization |
ISO |
Clotrimazole affects the localization of ALDOB protein |
CTD |
PMID:12126931 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Ankrd40 |
ankyrin repeat domain 40 |
increases expression |
EXP |
Clotrimazole results in increased expression of ANKRD40 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320 Ensembl chr10:79,282,075...79,295,320
|
|
G |
Apoe |
apolipoprotein E |
decreases expression |
EXP |
Clotrimazole results in decreased expression of APOE mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arrdc1 |
arrestin domain containing 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ARRDC1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:7,735,002...7,742,195
Ensembl chr 3:7,735,011...7,742,197
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Clotrimazole results in increased expression of ATF3 mRNA SB 203580 inhibits the reaction [Clotrimazole results in increased expression of ATF3 mRNA] |
CTD |
PMID:27507784 PMID:27965148 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
increases expression |
EXP |
Clotrimazole results in increased expression of ATP5F1C mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
increases expression |
EXP |
Clotrimazole results in increased expression of ATP5PB mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
increases expression |
EXP |
Clotrimazole results in increased expression of ATP5PD mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atpaf2 |
ATP synthase mitochondrial F1 complex assembly factor 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of ATPAF2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:45,205,658...45,221,891
Ensembl chr10:45,197,441...45,221,026
|
|
G |
Azi2 |
5-azacytidine induced 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of AZI2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:117,773,248...117,797,844
Ensembl chr 8:117,773,279...117,797,847
|
|
G |
Batf3 |
basic leucine zipper ATF-like transcription factor 3 |
increases expression |
EXP |
Clotrimazole results in increased expression of BATF3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139
|
|
G |
Bbs4 |
Bardet-Biedl syndrome 4 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of BBS4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:59,731,912...59,765,408
Ensembl chr 8:59,731,912...59,765,607
|
|
G |
Bckdha |
branched chain keto acid dehydrogenase E1 subunit alpha |
decreases expression |
EXP |
Clotrimazole results in decreased expression of BCKDHA mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:81,138,946...81,167,765
Ensembl chr 1:81,138,947...81,167,862
|
|
G |
Bhlhe22 |
basic helix-loop-helix family, member e22 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of BHLHE22 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:100,486,400...100,489,510
Ensembl chr 2:100,486,400...100,489,510
|
|
G |
Bicd2 |
BICD cargo adaptor 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of BICD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:15,259,773...15,304,889
Ensembl chr17:15,259,773...15,304,889
|
|
G |
Bri3bp |
Bri3 binding protein |
increases expression |
EXP |
Clotrimazole results in increased expression of BRI3BP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572
|
|
G |
Btf3 |
basic transcription factor 3 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of BTF3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:29,659,764...29,666,898
Ensembl chr 2:29,659,231...29,666,879 Ensembl chr13:29,659,231...29,666,879
|
|
G |
C1qtnf1 |
C1q and TNF related 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of C1QTNF1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:103,660,319...103,681,662
Ensembl chr10:103,660,327...103,681,660
|
|
G |
C1qtnf5 |
C1q and TNF related 5 |
increases expression |
EXP |
Clotrimazole results in increased expression of C1QTNF5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074
|
|
G |
Cacnb1 |
calcium voltage-gated channel auxiliary subunit beta 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CACNB1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:82,998,182...83,018,838
Ensembl chr10:82,998,182...83,018,694
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Clotrimazole results in increased expression of CALR mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp12 |
caspase 12 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CASP12 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Clotrimazole inhibits the reaction [Benzo(a)pyrene results in increased expression of CASP3 mRNA] [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of CASP3 protein]; Clotrimazole inhibits the reaction [lead acetate results in increased activity of CASP3 protein] |
CTD |
PMID:22033380 PMID:24239969 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of CASP8 protein]; Clotrimazole inhibits the reaction [lead acetate results in increased activity of CASP8 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in decreased activity of CAT protein]; Clotrimazole inhibits the reaction [lead acetate results in decreased activity of CAT protein] |
CTD |
PMID:22033380 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc17 |
coiled-coil domain containing 17 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CCDC17 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:130,051,158...130,056,676
Ensembl chr 5:130,045,938...130,056,673
|
|
G |
Ccdc28a |
coiled-coil domain containing 28A |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CCDC28A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:12,857,668...12,872,944
Ensembl chr 1:12,857,666...12,873,003
|
|
G |
Ccsap |
centriole, cilia and spindle-associated protein |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CCSAP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753
|
|
G |
Cd81 |
Cd81 molecule |
increases expression |
EXP |
Clotrimazole results in increased expression of CD81 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd93 |
CD93 molecule |
increases expression |
EXP |
Clotrimazole results in increased expression of CD93 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdip1 |
cell death-inducing p53 target 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CDIP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:10,773,538...10,796,979
Ensembl chr10:10,774,705...10,796,980
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Clotrimazole results in decreased expression of CDK1 |
CTD |
PMID:20724915 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Clotrimazole results in decreased expression of CDK4 |
CTD |
PMID:20724915 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
Clotrimazole results in decreased expression of CDKN1A |
CTD |
PMID:20724915 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Clotrimazole results in increased expression of CDKN1B |
CTD |
PMID:20724915 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2aip |
CDKN2A interacting protein |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CDKN2AIP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr16:44,536,147...44,546,216
Ensembl chr16:44,536,234...44,540,033
|
|
G |
Cenpj |
centromere protein J |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CPAP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr15:30,627,206...30,690,384
Ensembl chr15:30,627,224...30,686,791
|
|
G |
Chchd1 |
coiled-coil-helix-coiled-coil-helix domain containing 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of CHCHD1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr15:3,592,719...3,593,901
Ensembl chr15:3,592,727...3,593,901
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CHD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of CHST1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Cimap1c |
ciliary microtubule associated protein 1C |
increases expression |
EXP |
Clotrimazole results in increased expression of CIMAP1C mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:57,248,746...57,281,084
Ensembl chr 8:57,248,746...57,281,004
|
|
G |
Cisd2 |
CDGSH iron sulfur domain 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of CISD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:223,828,937...223,853,768
Ensembl chr 2:223,828,937...223,868,946
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
increases expression |
EXP |
Clotrimazole results in increased expression of CLCN3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Clk2 |
CDC-like kinase 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CLK2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985
|
|
G |
Cnn2 |
calponin 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of CNN2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
Clotrimazole results in decreased expression of COL1A1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
EXP |
Clotrimazole results in increased expression of COL6A2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
decreases expression |
EXP |
Clotrimazole results in decreased expression of COL7A1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Col9a2 |
collagen type IX alpha 2 chain |
decreases expression |
EXP |
Clotrimazole results in decreased expression of COL9A2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:134,607,616...134,624,678
Ensembl chr 5:134,607,616...134,624,677
|
|
G |
Commd2 |
COMM domain containing 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of COMMD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:141,848,661...141,852,907
Ensembl chr 2:141,848,680...141,852,888
|
|
G |
Coro2b |
coronin 2B |
increases expression |
EXP |
Clotrimazole results in increased expression of CORO2B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:62,906,861...63,017,295
Ensembl chr 8:62,906,867...63,017,302
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
increases expression |
EXP |
Clotrimazole results in increased expression of COX7A2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633 Ensembl chr 8:51,301,168...51,301,633
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
increases expression |
EXP |
Clotrimazole results in increased expression of COX8A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:204,402,118...204,404,439
|
|
G |
Cpz |
carboxypeptidase Z |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CPZ mRNA |
CTD |
PMID:30047161 |
|
NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Creb3l2 |
cAMP responsive element binding protein 3-like 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of CREB3L2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:65,907,570...66,112,078
Ensembl chr 4:65,907,655...66,023,763
|
|
G |
Crisp1 |
cysteine-rich secretory protein 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CRISP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Clotrimazole results in decreased activity of CYP17A1 protein |
CTD |
PMID:31330226 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Clotrimazole results in decreased activity of CYP19A1 protein |
CTD |
PMID:15554355 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases activity |
EXP ISO |
Clotrimazole results in increased expression of CYP1A1 protein Clotrimazole results in decreased activity of CYP1A1 protein |
CTD |
PMID:7986207 PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
EXP |
Clotrimazole results in increased expression of CYP1A2 protein Clotrimazole inhibits the reaction [CYP1A2 protein results in increased metabolism of 3-cyano-7-ethoxycoumarin] |
CTD |
PMID:7986207 PMID:19858067 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Clotrimazole results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Clotrimazole inhibits the reaction [CYP2A2 protein results in increased metabolism of 7-benzyloxyquinoline] |
CTD |
PMID:19858067 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases activity increases expression |
EXP |
Clotrimazole inhibits the reaction [CYP2B1 protein results in increased metabolism of 7-benzyloxy-4-trifluoromethylcoumarin] Clotrimazole results in increased activity of CYP2B1 protein Clotrimazole results in increased expression of CYP2B1 mRNA; Clotrimazole results in increased expression of CYP2B1 protein |
CTD |
PMID:1372805 PMID:7986207 PMID:19858067 PMID:36356836 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of CYP2B2 mRNA; Clotrimazole results in increased expression of CYP2B2 protein |
CTD |
PMID:7986207 PMID:12971794 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression increases activity |
ISO |
Clotrimazole results in increased expression of and results in increased activity of CYP2B6 protein; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP2B6 mRNA]]]; NR1I2 protein affects the reaction [Clotrimazole results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP2B6 mRNA] NR1I3 protein affects the reaction [Clotrimazole results in increased expression of CYP2B10 mRNA] Clotrimazole results in increased expression of CYP2B6 protein Clotrimazole results in increased activity of CYP2B6 protein |
CTD |
PMID:12049174 PMID:12571232 PMID:12695351 PMID:14977870 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions decreases expression |
EXP |
Clotrimazole inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] Clotrimazole results in decreased expression of CYP2C11 protein |
CTD |
PMID:7986207 PMID:19858067 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
EXP |
Clotrimazole inhibits the reaction [CYP2C6 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Clotrimazole results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 PMID:33775687 |
|
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
Clotrimazole inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2j3 |
cytochrome P450, family 2, subfamily j, polypeptide 3 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of CYP2J3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:111,219,921...111,244,987
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases activity increases expression increases activity |
EXP ISO |
Clotrimazole inhibits the reaction [CYP3A2 protein results in increased metabolism of 7-benzyloxyquinoline] Clotrimazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Clotrimazole promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP3A4 mRNA] Clotrimazole results in decreased activity of CYP3A4 protein Clotrimazole results in increased expression of CYP3A4 mRNA; Clotrimazole results in increased expression of CYP3A4 protein Clotrimazole results in increased activity of CYP3A4 protein |
CTD |
PMID:8632764 PMID:12065438 PMID:12505310 PMID:12673034 PMID:14977870 PMID:15135088 PMID:15466163 PMID:16837568 PMID:17998298 PMID:19299527 PMID:19858067 PMID:27507784 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression multiple interactions |
EXP |
Clotrimazole results in increased expression of CYP3A23-3A1 mRNA Clotrimazole inhibits the reaction [CYP3A23-3A1 protein results in increased metabolism of 7-benzyloxyquinoline] |
CTD |
PMID:12971794 PMID:16125621 PMID:19858067 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
Clotrimazole results in increased expression of CYP3A5 protein |
CTD |
PMID:8632764 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity decreases response to substance |
ISO |
Clotrimazole results in decreased activity of CYP51A1 protein CYP51A1 gene results in decreased susceptibility to Clotrimazole |
CTD |
PMID:16989930 PMID:18694951 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Dab2 |
DAB adaptor protein 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of DAB2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dbn1 |
drebrin 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of DBN1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dchs1 |
dachsous cadherin-related 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of DCHS1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:160,104,931...160,138,958
Ensembl chr 1:160,104,931...160,124,808
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of DCLK1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Ddx39a |
DExD-box helicase 39A |
increases expression |
EXP |
Clotrimazole results in increased expression of DDX39A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
Clotrimazole results in increased expression of DNAJB4 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Doc2b |
double C2 domain beta |
increases expression |
EXP |
Clotrimazole results in increased expression of DOC2B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:60,628,029...60,653,267
Ensembl chr10:60,628,029...60,653,267
|
|
G |
Dok4 |
docking protein 4 |
increases expression |
EXP |
Clotrimazole results in increased expression of DOK4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203
|
|
G |
Dph3 |
diphthamide biosynthesis 3 |
increases expression |
EXP |
Clotrimazole results in increased expression of DPH3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr16:7,288,295...7,293,734
Ensembl chr16:7,282,705...7,291,265
|
|
G |
Dpm1 |
dolichyl-phosphate mannosyltransferase subunit 1, catalytic |
increases expression |
EXP |
Clotrimazole results in increased expression of DPM1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:156,919,979...156,939,522
Ensembl chr 3:156,919,979...156,939,536
|
|
G |
Dscam |
DS cell adhesion molecule |
decreases expression |
EXP |
Clotrimazole results in decreased expression of DSCAM mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:35,921,924...36,507,100
Ensembl chr11:35,926,896...36,507,415
|
|
G |
Eid2 |
EP300 interacting inhibitor of differentiation 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of EID2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:83,538,274...83,539,599
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
multiple interactions increases phosphorylation |
ISO |
[Clotrimazole results in increased phosphorylation of EIF2A protein] which results in increased expression of TMEFF2 protein |
CTD |
PMID:23405127 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Eng |
endoglin |
increases expression |
EXP |
Clotrimazole results in increased expression of ENG mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of EPB41L2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases activity |
EXP |
Clotrimazole results in increased activity of EPHX1 protein |
CTD |
PMID:1372805 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Eps8l1 |
EPS8-like 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of EPS8L1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:69,343,202...69,359,778
Ensembl chr 1:69,344,243...69,363,524
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ERN1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esam |
endothelial cell adhesion molecule |
increases expression |
EXP |
Clotrimazole results in increased expression of ESAM mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
Clotrimazole inhibits the reaction [F2RL1 protein results in increased transport of Chlorides] |
CTD |
PMID:11804840 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Fam110b |
family with sequence similarity 110, member B |
decreases expression |
EXP |
Clotrimazole results in decreased expression of FAM110B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828
|
|
G |
Fam120b |
family with sequence similarity 120 member B |
increases expression |
EXP |
Clotrimazole results in increased expression of FAM120B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:56,320,015...56,385,064
Ensembl chr 1:56,339,129...56,385,061
|
|
G |
Fam124a |
family with sequence similarity 124 member A |
decreases expression |
EXP |
Clotrimazole results in decreased expression of FAM124A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr15:36,799,836...36,855,062
Ensembl chr15:36,799,877...36,853,683
|
|
G |
Fam167b |
family with sequence similarity 167, member B |
increases expression |
EXP |
Clotrimazole results in increased expression of FAM167B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:141,920,695...141,922,342
Ensembl chr 5:141,920,695...141,922,340
|
|
G |
Fanci |
FA complementation group I |
increases expression |
EXP |
Clotrimazole results in increased expression of FANCI mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate affects the localization of and results in increased activity of FAS protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of FHL2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Clotrimazole results in decreased expression of FOS protein |
CTD |
PMID:10223459 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fstl1 |
follistatin-like 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of FSTL1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:62,895,391...62,948,581
Ensembl chr11:62,779,783...62,948,677
|
|
G |
Fxyd5 |
FXYD domain-containing ion transport regulator 5 |
increases expression |
EXP |
Clotrimazole results in increased expression of FXYD5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:86,267,937...86,277,329
Ensembl chr 1:86,267,406...86,277,519
|
|
G |
Galr2 |
galanin receptor 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GALR2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176
|
|
G |
Ganc |
glucosidase, alpha; neutral C |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GANC mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GAP43 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Garin5a |
golgi associated RAB2 interactor 5A |
decreases expression |
EXP |
Clotrimazole results in decreased expression of FAM71E1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:94,988,959...94,995,971
Ensembl chr 1:94,988,613...94,993,539
|
|
G |
Gemin7l1 |
gem (nuclear organelle) associated protein 7-like 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of GEMIN7L1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:78,269,910...78,270,681
Ensembl chr 4:78,269,888...78,270,669
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
Clotrimazole results in increased expression of GFAP protein |
CTD |
PMID:10223459 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gldn |
gliomedin |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GLDN mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:54,679,119...54,723,196
|
|
G |
Glrx2 |
glutaredoxin 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of GLRX2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased expression of GOT1 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpc3 |
glypican 3 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GPC3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Gpr62 |
G protein-coupled receptor 62 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GPR62 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:107,103,225...107,105,311
Ensembl chr 8:107,103,980...107,105,056
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased expression of GPT protein] |
CTD |
PMID:22033380 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gramd1a |
GRAM domain containing 1A |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GRAMD1A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336
|
|
G |
Grina |
glutamate ionotropic receptor NMDA type subunit associated protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of GRINA mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 7:107,962,194...107,965,372
Ensembl chr 7:107,962,207...107,965,366
|
|
G |
Gse1 |
Gse1 coiled-coil protein |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GSE1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:48,274,164...48,629,456
Ensembl chr19:48,274,127...48,629,458
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of GSTA2 mRNA |
CTD |
PMID:12971794 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of GSTM2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Clotrimazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Guca1a |
guanylate cyclase activator 1A |
increases expression |
EXP |
Clotrimazole results in increased expression of GUCA1A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:13,588,988...13,598,566
Ensembl chr 9:13,588,525...13,598,565
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of GUCY1A3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Herc1 |
HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of HERC1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:66,857,169...67,070,318
Ensembl chr 8:66,856,935...67,070,312
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of HIP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
increases expression |
EXP |
Clotrimazole results in increased expression of HIST1H2BD mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hk2 |
hexokinase 2 |
affects localization decreases expression |
ISO |
Clotrimazole affects the localization of HK2 protein Clotrimazole results in decreased expression of HK2 mRNA |
CTD |
PMID:20724915 PMID:25863232 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of HMGB1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hps4 |
HPS4, biogenesis of lysosomal organelles complex 3 subunit 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of HPS4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:44,264,037...44,294,791
Ensembl chr12:44,264,037...44,294,632
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Clotrimazole results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
EXP |
Clotrimazole results in increased expression of HSPA4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of HSPE1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Ifi44 |
interferon-induced protein 44 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of IFI44 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
|
|
G |
Ifnar2 |
interferon alpha and beta receptor subunit 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of IFNAR2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:30,613,576...30,645,958
Ensembl chr11:30,613,767...30,668,124
|
|
G |
Igf2bp2 |
insulin-like growth factor 2 mRNA binding protein 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of IGF2BP2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:78,874,402...78,974,392
Ensembl chr11:78,874,414...78,974,377
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression increases secretion |
ISO |
Clotrimazole results in increased expression of IGFBP1 mRNA Clotrimazole results in increased secretion of IGFBP1 protein |
CTD |
PMID:12659874 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igsf10 |
immunoglobulin superfamily, member 10 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of IGSF10 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:143,575,710...143,605,044
Ensembl chr 2:143,576,070...143,604,773
|
|
G |
Il34 |
interleukin 34 |
increases expression |
EXP |
Clotrimazole results in increased expression of IL34 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:38,714,990...38,782,749
Ensembl chr19:38,714,991...38,764,000
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
increases expression |
EXP |
Clotrimazole results in increased expression of INPP5D mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Ints14 |
integrator complex subunit 14 |
increases expression |
EXP |
Clotrimazole results in increased expression of VWA9 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:65,475,788...65,500,807
Ensembl chr 8:65,475,910...65,500,804
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of IP6K2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166
|
|
G |
Itga9 |
integrin subunit alpha 9 |
increases expression |
EXP |
Clotrimazole results in increased expression of ITGA9 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:118,307,424...118,615,527
Ensembl chr 8:118,307,381...118,613,754
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of ITGB1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itih3 |
inter-alpha trypsin inhibitor, heavy chain 3 |
increases expression |
EXP |
Clotrimazole results in increased expression of ITIH3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Clotrimazole results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj1 |
potassium inwardly-rectifying channel, subfamily J, member 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of KCNJ1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:30,779,883...30,808,607
Ensembl chr 8:30,753,617...30,813,796
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
multiple interactions decreases activity |
ISO |
Clotrimazole inhibits the reaction [[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein] [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of KCNN4 protein]; Clotrimazole inhibits the reaction [lead acetate results in increased activity of KCNN4 protein] Clotrimazole results in decreased activity of KCNN4 protein |
CTD |
PMID:14985237 PMID:15921678 PMID:17699636 PMID:20050851 PMID:22033380 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Kdm4a |
lysine demethylase 4A |
decreases expression |
EXP |
Clotrimazole results in decreased expression of KDM4A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LCAT mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lhfpl5 |
LHFPL tetraspan subfamily member 5 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LHFPL5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:6,632,324...6,642,534
Ensembl chr20:6,632,362...6,642,532
|
|
G |
Lims2 |
LIM zinc finger domain containing 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LIMS2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr18:23,553,937...23,592,137
Ensembl chr18:23,553,937...23,592,137
|
|
G |
Lipg |
lipase G, endothelial type |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LIPG mRNA |
CTD |
PMID:30047161 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of LOXL1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LRP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Lsamp |
limbic system-associated membrane protein |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LSAMP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:58,547,533...60,717,328
Ensembl chr11:58,554,805...60,717,029
|
|
G |
Ltbp4 |
latent transforming growth factor beta binding protein 4 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of LTBP4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:82,600,136...82,634,346
Ensembl chr 1:82,600,136...82,632,178
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
MAPK14 promotes the reaction [Clotrimazole results in increased expression of ABCC3 mRNA] |
CTD |
PMID:27507784 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
EXP |
Clotrimazole results in decreased expression of MAPT mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
EXP |
Clotrimazole results in increased expression of MARCKS mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
|
|
G |
Mark3 |
microtubule affinity regulating kinase 3 |
increases expression |
EXP |
Clotrimazole results in increased expression of MARK3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:130,626,612...130,716,245
Ensembl chr 6:130,627,482...130,716,647
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of MBNL1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368
|
|
G |
Mcfd2 |
multiple coagulation factor deficiency 2, ER cargo receptor complex subunit |
increases expression |
EXP |
Clotrimazole results in increased expression of MCFD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:7,274,469...7,285,841
Ensembl chr 6:7,274,469...7,285,841
|
|
G |
Mfap2 |
microfibril associated protein 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of MFAP2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259
|
|
G |
Mipol1 |
mirror-image polydactyly 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of MIPOL1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:74,755,293...75,090,403
Ensembl chr 6:74,755,395...75,086,811
|
|
G |
Mir96 |
microRNA 96 |
increases expression |
EXP |
Clotrimazole results in increased expression of MIR96 mRNA |
CTD |
PMID:27427493 |
|
NCBI chr 4:58,788,411...58,788,516
Ensembl chr 4:58,788,411...58,788,516
|
|
G |
Mllt3 |
MLLT3, super elongation complex subunit |
increases expression |
EXP |
Clotrimazole results in increased expression of MLLT3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:102,259,075...102,515,447
Ensembl chr 5:102,260,011...102,515,361
|
|
G |
Mturn |
maturin, neural progenitor differentiation regulator homolog |
decreases expression |
EXP |
Clotrimazole results in decreased expression of MTURN mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:83,807,528...83,828,494
Ensembl chr 4:83,807,579...83,824,950
|
|
G |
Mxra8 |
matrix remodeling associated 8 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of MXRA8 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:166,448,919...166,453,645
Ensembl chr 5:166,449,154...166,453,636
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Clotrimazole results in decreased expression of MYC protein |
CTD |
PMID:10223459 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myct1 |
myc target 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of MYCT1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410
|
|
G |
Myef2 |
myelin expression factor 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of MYEF2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:112,338,241...112,374,122
Ensembl chr 3:112,338,241...112,374,181
|
|
G |
Myl9 |
myosin light chain 9 |
increases expression |
EXP |
Clotrimazole results in increased expression of MYL9 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Myo16 |
myosin XVI |
increases expression |
EXP |
Clotrimazole results in increased expression of MYO16 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr16:78,884,405...79,364,445
Ensembl chr16:78,884,406...79,248,388
|
|
G |
Myo1b |
myosin Ib |
increases expression |
EXP |
Clotrimazole results in increased expression of MYO1B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798
|
|
G |
Naaladl2 |
N-acetylated alpha-linked acidic dipeptidase-like 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NAALADL2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:106,639,146...107,992,218
Ensembl chr 2:106,645,608...107,991,689
|
|
G |
Nacc2 |
NACC family member 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NACC2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:8,879,952...8,946,660
Ensembl chr 3:8,883,065...8,946,660
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Clotrimazole promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein] Clotrimazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Clotrimazole promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein] |
CTD |
PMID:17998298 PMID:18973326 PMID:21924250 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
Clotrimazole promotes the reaction [NR1I3 protein modified form binds to NCOR1 protein] |
CTD |
PMID:18973326 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ndfip2 |
Nedd4 family interacting protein 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of NDFIP2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr15:82,032,366...82,087,043
Ensembl chr15:82,032,366...82,086,317
|
|
G |
Ndufa5 |
NADH:ubiquinone oxidoreductase subunit A5 |
increases expression |
EXP |
Clotrimazole results in increased expression of NDUFA5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598 Ensembl chr 5:52,995,546...53,005,598
|
|
G |
Ndufaf7 |
NADH:ubiquinone oxidoreductase complex assembly factor 7 |
increases expression |
EXP |
Clotrimazole results in increased expression of NDUFAF7 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:16,108,630...16,119,810
Ensembl chr 6:16,103,003...16,119,810
|
|
G |
Ndufb5 |
NADH:ubiquinone oxidoreductase subunit B5 |
increases expression |
EXP |
Clotrimazole results in increased expression of NDUFB5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589
|
|
G |
Ndufs3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
increases expression |
EXP |
Clotrimazole results in increased expression of NDUFS3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824
|
|
G |
Ndufs6 |
NADH:ubiquinone oxidoreductase subunit S6 |
increases expression |
EXP |
Clotrimazole results in increased expression of NDUFS6 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:29,968,833...29,977,423
Ensembl chr 1:29,968,842...29,977,467
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NEDD4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of FAM129A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nid1 |
nidogen 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of NID1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:86,085,133...86,158,272
Ensembl chr17:86,085,077...86,158,267
|
|
G |
Nipsnap1 |
nipsnap homolog 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NIPSNAP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098
|
|
G |
Nipsnap3a |
nipsnap homolog 3A (C. elegans) |
increases expression |
EXP |
Clotrimazole results in increased expression of NIPSNAP3B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:67,613,993...67,625,067
Ensembl chr 5:67,614,036...67,669,700
|
|
G |
Nob1 |
NIN1 (RPN12) binding protein 1 homolog |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NOB1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr19:35,322,803...35,335,354
Ensembl chr19:35,322,669...35,346,815
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity increases expression |
ISO EXP |
Clotrimazole binds to and results in increased activity of NR1I2 protein; Clotrimazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Clotrimazole promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP2B6 mRNA]]]; NR1I2 protein affects the reaction [Clotrimazole results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP3A4 mRNA] Clotrimazole results in increased activity of NR1I2 protein Clotrimazole results in increased expression of NR1I2 mRNA |
CTD |
PMID:12049174 PMID:12065438 PMID:12695351 PMID:14977870 PMID:15548381 PMID:15849716 PMID:16919048 PMID:17998298 PMID:20869355 PMID:23899473 PMID:25680588 PMID:26187274 PMID:27507784 PMID:27732639 PMID:28259787 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions decreases activity increases activity affects binding |
ISO EXP |
1,1-bis(4-hydroxyphenyl)cyclohexane inhibits the reaction [Clotrimazole binds to NR1I3 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Clotrimazole binds to NR1I3 protein]; androstan-3-ol inhibits the reaction [Clotrimazole binds to NR1I3 protein]; bisphenol A inhibits the reaction [Clotrimazole binds to NR1I3 protein]; bisphenol B inhibits the reaction [Clotrimazole binds to NR1I3 protein]; Clotrimazole binds to and affects the activity of NR1I3 protein; Clotrimazole binds to and results in decreased activity of NR1I3 protein; Clotrimazole binds to and results in increased activity of and results in increased localization of NR1I3 protein mutant form; Clotrimazole binds to and results in increased activity of NR1I3 protein alternative form; Clotrimazole inhibits the reaction [4-nonylphenol results in increased activity of NR1I3 protein]; Clotrimazole inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime binds to and results in increased activity of NR1I3 protein mutant form]; Clotrimazole promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein] Clotrimazole results in decreased activity of NR1I3 protein Clotrimazole results in increased activity of NR1I3 protein; Clotrimazole results in increased activity of NR1I3 protein alternative form Clotrimazole results in decreased activity of NR1I3 protein; Clotrimazole results in decreased activity of NR1I3 protein alternative form Clotrimazole results in increased activity of NR1I3 protein; Clotrimazole results in increased activity of NR1I3 protein alternative form; Clotrimazole results in increased activity of NR1I3 protein mutant form androstan-3-ol inhibits the reaction [Clotrimazole results in increased activity of NR1I3 protein mutant form]; Clotrimazole inhibits the reaction [androstan-3-ol results in decreased activity of NR1I3 protein alternative form]; Clotrimazole inhibits the reaction [Imidazoles results in decreased activity of NR1I3 protein alternative form]; Imidazoles inhibits the reaction [Clotrimazole results in increased activity of NR1I3 protein mutant form] Clotrimazole results in increased activity of NR1I3 protein; Clotrimazole results in increased activity of NR1I3 protein mutant form Clotrimazole promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]; Clotrimazole promotes the reaction [NR1I3 protein modified form binds to NCOR1 protein]; NR1I3 protein affects the reaction [Clotrimazole results in increased expression of CYP2B10 mRNA] |
CTD |
PMID:12049174 PMID:15905360 PMID:16919048 PMID:18973326 PMID:20686338 PMID:20869355 PMID:21315811 PMID:21778469 PMID:21924250 PMID:23015691 PMID:23899473 PMID:25625231 PMID:26187274 PMID:27732639 PMID:31195007 PMID:31312845 More...
|
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Clotrimazole results in increased expression of CYP2B6 mRNA]]] |
CTD |
PMID:12695351 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NRCAM mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
|
|
G |
Nsfl1c |
NSFL1 cofactor |
increases expression |
EXP |
Clotrimazole results in increased expression of NSFL1C mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870
|
|
G |
Nudcd2 |
NudC domain containing 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of NUDCD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:25,163,247...25,168,738
Ensembl chr10:25,163,220...25,168,738
|
|
G |
Nudt12 |
nudix hydrolase 12 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of NUDT12 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:98,741,627...98,755,039
Ensembl chr 9:98,742,360...98,755,039
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of ODC1 mRNA |
CTD |
PMID:12971794 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Optn |
optineurin |
increases expression |
EXP |
Clotrimazole results in increased expression of OPTN mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of ORC1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of P2RX3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
Pcnx4 |
pecanex 4 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PCNXL4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:91,125,063...91,170,423
Ensembl chr 6:91,125,063...91,170,439
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
increases expression |
EXP |
Clotrimazole results in increased expression of PDGFRB mRNA |
CTD |
PMID:30047161 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdhx |
pyruvate dehydrogenase complex, component X |
increases expression |
EXP |
Clotrimazole results in increased expression of PDHX mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:89,372,248...89,431,779
Ensembl chr 3:89,371,497...89,431,773
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
increases expression |
EXP |
Clotrimazole results in increased expression of PDIA4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pex2 |
peroxisomal biogenesis factor 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of PEX2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:96,050,380...96,072,928
Ensembl chr 2:96,045,958...96,073,404
|
|
G |
Pfkm |
phosphofructokinase, muscle |
decreases expression |
ISO |
Clotrimazole results in decreased expression of PFKM mRNA |
CTD |
PMID:25863232 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pfkp |
phosphofructokinase, platelet |
affects localization |
ISO |
Clotrimazole affects the localization of PFKP protein |
CTD |
PMID:12126931 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Phf1 |
PHD finger protein 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PHF1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:5,017,765...5,022,872
Ensembl chr20:5,017,893...5,022,871
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PIAS1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
|
|
G |
Pink1 |
PTEN induced kinase 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PINK1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pla1a |
phospholipase A1 member A |
increases expression |
EXP |
Clotrimazole results in increased expression of PLA1A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:62,320,112...62,357,779
Ensembl chr11:62,320,493...62,357,779
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PLAU mRNA |
CTD |
PMID:30047161 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plch2 |
phospholipase C, eta 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PLCH2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:165,544,209...165,613,769
Ensembl chr 5:165,544,200...165,602,356
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
EXP |
Clotrimazole results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Podxl |
podocalyxin-like |
increases expression |
EXP |
Clotrimazole results in increased expression of PODXL mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Pole3 |
DNA polymerase epsilon 3, accessory subunit |
increases expression |
EXP |
Clotrimazole results in increased expression of POLE3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:75,973,941...75,977,175
Ensembl chr 5:75,974,717...75,977,231 Ensembl chr 7:75,974,717...75,977,231
|
|
G |
Ppm1j |
protein phosphatase, Mg2+/Mn2+ dependent, 1J |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PPM1J mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882
|
|
G |
Ppp1r9a |
protein phosphatase 1, regulatory subunit 9A |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PPP1R9A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
|
|
G |
Prdx2 |
peroxiredoxin 2 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate affects the localization of PRDX2 protein]; [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate promotes the reaction [PRDX2 protein binds to PRDX2 protein]]; Clotrimazole inhibits the reaction [lead acetate promotes the reaction [PRDX2 protein binds to PRDX2 protein]] |
CTD |
PMID:22033380 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prkch |
protein kinase C, eta |
increases expression |
EXP |
Clotrimazole results in increased expression of PRKCH mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:92,292,000...92,490,663
Ensembl chr 6:92,292,000...92,490,654
|
|
G |
Prkd2 |
protein kinase D2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PRKD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:77,513,625...77,542,386
Ensembl chr 1:77,513,986...77,542,376
|
|
G |
Prrx1 |
paired related homeobox 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of PRRX1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866
|
|
G |
Prss41 |
serine protease 41 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of PRSS41 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:12,865,872...12,873,552
Ensembl chr10:12,865,872...12,873,552
|
|
G |
Psip1 |
PC4 and SRSF1 interacting protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of PSIP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257
|
|
G |
Ptgfrn |
prostaglandin F2 receptor inhibitor |
increases expression |
EXP |
Clotrimazole results in increased expression of PTGFRN mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:188,469,521...188,544,795
Ensembl chr 2:188,469,521...188,544,795
|
|
G |
Rab11fip4 |
RAB11 family interacting protein 4 |
increases expression |
EXP |
Clotrimazole results in increased expression of RAB11FIP4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:64,550,109...64,658,123
Ensembl chr10:64,550,177...64,654,759
|
|
G |
Rab9a |
RAB9A, member RAS oncogene family |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RAB9A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr X:27,955,552...28,009,870
Ensembl chr X:27,952,204...28,001,622
|
|
G |
Rad18 |
RAD18 E3 ubiquitin protein ligase |
increases expression |
EXP |
Clotrimazole results in increased expression of RAD18 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069
|
|
G |
Ralbp1 |
ralA binding protein 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RALBP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:105,456,425...105,493,235
Ensembl chr 9:105,456,425...105,492,707
|
|
G |
Rasip1 |
Ras interacting protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of RASIP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:96,097,135...96,109,564
Ensembl chr 1:96,091,074...96,109,562
|
|
G |
Rbp2 |
retinol binding protein 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of RBP2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:99,079,293...99,104,489
Ensembl chr 8:99,079,104...99,104,473
|
|
G |
Rfc2 |
replication factor C subunit 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of RFC2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:22,120,449...22,133,576
Ensembl chr12:22,120,010...22,133,557
|
|
G |
Rftn2 |
raftlin family member 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RFTN2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 9:56,651,617...56,707,830
Ensembl chr 9:56,630,460...56,707,810
|
|
G |
Rgn |
regucalcin |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RGN mRNA |
CTD |
PMID:12971794 |
|
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
|
|
G |
Rgs5 |
regulator of G-protein signaling 5 |
increases expression |
EXP |
Clotrimazole results in increased expression of RGS5 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
|
|
G |
Rgs9bp |
regulator of G protein signaling 9 binding protein |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RGS9BP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:88,249,438...88,250,151
Ensembl chr 1:88,249,438...88,250,151
|
|
G |
Rilpl1 |
Rab interacting lysosomal protein-like 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RILPL1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:32,071,870...32,109,687
Ensembl chr12:32,071,693...32,109,938
|
|
G |
Rnf8 |
ring finger protein 8 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RNF8 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:7,682,258...7,710,448
Ensembl chr20:7,682,322...7,708,491
|
|
G |
Rps27l |
ribosomal protein S27-like |
increases expression |
EXP |
Clotrimazole results in increased expression of RPS27L mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418 Ensembl chr12:67,562,483...67,567,418 Ensembl chr 2:67,562,483...67,567,418
|
|
G |
Rps6kb2 |
ribosomal protein S6 kinase B2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RPS6KB2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:201,451,265...201,458,096
Ensembl chr 1:201,451,265...201,458,078
|
|
G |
Rsbn1 |
round spermatid basic protein 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RSBN1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:191,416,631...191,470,711
Ensembl chr 2:191,416,631...191,470,711
|
|
G |
Schip1 |
schwannomin interacting protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of SCHIP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:152,127,171...152,888,587
Ensembl chr 2:152,126,953...152,888,585
|
|
G |
Sdhd |
succinate dehydrogenase complex subunit D |
increases expression |
EXP |
Clotrimazole results in increased expression of SDHD mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:50,944,702...50,954,298
Ensembl chr 8:50,944,704...50,954,238
|
|
G |
Senp7 |
SUMO specific peptidase 7 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SENP7 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr11:44,423,733...44,584,129
Ensembl chr11:44,423,735...44,564,711
|
|
G |
Senp8 |
SUMO peptidase family member, NEDD8 specific |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SENP8 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:60,135,446...60,148,836
Ensembl chr 8:60,121,714...60,148,928
|
|
G |
Serpinf1 |
serpin family F member 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SERPINF1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of SGK1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Siglec1 |
sialic acid binding Ig like lectin 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SIGLEC1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:118,287,988...118,307,125
Ensembl chr 3:118,287,988...118,306,850
|
|
G |
Sipa1 |
signal-induced proliferation-associated 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of SIPA1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:202,938,532...202,950,672
Ensembl chr 1:202,938,580...202,950,591
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
multiple interactions decreases activity |
EXP |
Clotrimazole inhibits the reaction [SLC19A1 protein results in increased uptake of Methotrexate] Clotrimazole results in decreased activity of SLC19A1 protein |
CTD |
PMID:17482559 |
|
NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972
|
|
G |
Slc25a14 |
solute carrier family 25 member 14 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SLC25A14 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr X:127,807,630...127,845,823
Ensembl chr X:127,807,449...127,845,823
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of SMPD1 protein]; Clotrimazole inhibits the reaction [lead acetate results in increased activity of SMPD1 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
|
|
G |
Snrnp27 |
small nuclear ribonucleoprotein U4/U6.U5 subunit 27 |
increases expression |
EXP |
Clotrimazole results in increased expression of SNRNP27 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:119,123,676...119,133,234
Ensembl chr 4:119,121,877...119,133,234
|
|
G |
Snx16 |
sorting nexin 16 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SNX16 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:91,335,896...91,357,622
Ensembl chr 2:91,336,092...91,357,619
|
|
G |
Snx24 |
sorting nexin 24 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SNX24 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr18:46,670,987...46,826,070
Ensembl chr18:46,671,443...46,826,068
|
|
G |
Snx33 |
sorting nexin 33 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SNX33 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:57,315,861...57,328,522
Ensembl chr 8:57,317,161...57,327,538
|
|
G |
Sord |
sorbitol dehydrogenase |
increases expression |
EXP |
Clotrimazole results in increased expression of SORD mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Sptssa |
serine palmitoyltransferase, small subunit A |
increases expression |
EXP |
Clotrimazole results in increased expression of SPTSSA mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:72,144,714...72,156,130
Ensembl chr 6:72,144,714...72,156,214
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
EXP |
Clotrimazole results in increased expression of SRP9 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SRPX mRNA |
CTD |
PMID:30047161 |
|
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
|
|
G |
Srpx2 |
sushi-repeat-containing protein, X-linked 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of SRPX2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr X:97,106,455...97,132,197
Ensembl chr X:97,106,561...97,132,195
|
|
G |
Sspn |
sarcospan |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SSPN mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554
|
|
G |
Stac |
SH3 and cysteine rich domain |
increases expression |
EXP |
Clotrimazole results in increased expression of STAC mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:111,530,800...111,653,228
Ensembl chr 8:111,530,800...111,654,008
|
|
G |
Ston1 |
stonin 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of RAET1L mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:5,843,186...5,892,557
Ensembl chr 6:5,843,185...5,892,449
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of STYXL1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SULT1A1 mRNA |
CTD |
PMID:9566755 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:9566755 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Surf1 |
SURF1, cytochrome c oxidase assembly factor |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SURF1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:10,241,793...10,244,686
Ensembl chr 3:10,241,837...10,263,315
|
|
G |
Syne2 |
spectrin repeat containing nuclear envelope protein 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of SYNE2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064
|
|
G |
Tafazzin |
tafazzin, phospholipid-lysophospholipid transacylase |
increases expression |
EXP |
Clotrimazole results in increased expression of TAZ mRNA |
CTD |
PMID:30047161 |
|
NCBI chr X:152,065,539...152,076,178
Ensembl chr X:152,065,609...152,074,001
|
|
G |
Tagln |
transgelin |
increases expression |
EXP |
Clotrimazole results in increased expression of TAGLN mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tet3 |
tet methylcytosine dioxygenase 3 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TET3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:115,867,412...115,964,433
Ensembl chr 4:115,871,265...115,964,193
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of TGFB1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbi |
transforming growth factor, beta induced |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TGFBI mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240
|
|
G |
Thap3 |
THAP domain containing 3 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of THAP3 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:162,488,480...162,494,149
Ensembl chr 5:162,488,480...162,494,149
|
|
G |
Tmed4 |
transmembrane p24 trafficking protein 4 |
increases expression |
EXP |
Clotrimazole results in increased expression of TMED4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr14:81,125,049...81,129,646
Ensembl chr14:81,125,053...81,129,631
|
|
G |
Tmed7 |
transmembrane p24 trafficking protein 7 |
increases expression |
EXP |
Clotrimazole results in increased expression of TMED7 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr18:39,318,564...39,325,640
Ensembl chr18:39,297,351...39,325,640
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
ISO |
[Clotrimazole results in increased phosphorylation of EIF2A protein] which results in increased expression of TMEFF2 protein |
CTD |
PMID:23405127 |
|
NCBI chr 9:50,445,947...50,733,473
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tmem116 |
transmembrane protein 116 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TMEM116 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr12:35,021,912...35,089,409
Ensembl chr12:35,041,572...35,089,430
|
|
G |
Tmem39b |
transmembrane protein 39b |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TMEM39B mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:142,024,271...142,046,607
Ensembl chr 5:142,024,273...142,046,549
|
|
G |
Tmem88 |
transmembrane protein 88 |
increases expression |
EXP |
Clotrimazole results in increased expression of TMEM88 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:54,118,752...54,120,447
Ensembl chr10:54,118,752...54,120,447
|
|
G |
Tmem97 |
transmembrane protein 97 |
increases expression |
EXP |
Clotrimazole results in increased expression of TMEM97 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730
|
|
G |
Tmprss9 |
transmembrane serine protease 9 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TMPRSS9 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 7:8,810,321...8,831,177
Ensembl chr 7:8,810,320...8,831,177
|
|
G |
Tnks1bp1 |
tankyrase 1 binding protein 1 |
increases expression |
EXP |
Clotrimazole results in increased expression of TNKS1BP1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 3:70,135,335...70,160,071
Ensembl chr 3:70,137,837...70,160,038
|
|
G |
Tnxa-ps1 |
tenascin XA, pseudogene 1 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TNXA-PS1 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr20:4,026,471...4,027,826
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Clotrimazole results in increased expression of TP53 protein |
CTD |
PMID:10223459 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpm2 |
tropomyosin 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of TPM2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
|
|
G |
Traf4 |
Tnf receptor associated factor 4 |
increases expression |
EXP |
Clotrimazole results in increased expression of TRAF4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr10:63,054,169...63,060,284
Ensembl chr10:63,054,181...63,060,284
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases expression |
EXP |
Clotrimazole results in increased expression of TRPC6 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
EXP ISO |
Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] [Clotrimazole results in decreased activity of TRPM2 protein] inhibits the reaction [Mustard Gas results in increased abundance of Calcium] |
CTD |
PMID:21900507 PMID:22036725 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Tstd2 |
thiosulfate sulfurtransferase like domain containing 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TSTD2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:60,371,751...60,415,916
Ensembl chr 5:60,393,454...60,415,916
|
|
G |
Ttc33 |
tetratricopeptide repeat domain 33 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of TTC33 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:54,279,906...54,326,851
Ensembl chr 2:54,279,997...54,323,871
|
|
G |
Tubb2a |
tubulin, beta 2A class IIa |
increases expression |
EXP |
Clotrimazole results in increased expression of TUBB2A mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714
|
|
G |
Txlna |
taxilin alpha |
increases expression |
EXP |
Clotrimazole results in increased expression of TXLNA mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 5:141,969,337...141,985,054
Ensembl chr 5:141,969,346...141,984,583
|
|
G |
U2surp |
U2 snRNP-associated SURP domain containing |
decreases expression |
EXP |
Clotrimazole results in decreased expression of U2SURP mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 8:96,018,932...96,075,795
Ensembl chr 8:96,022,957...96,075,691
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression |
ISO |
Clotrimazole affects the expression of UGT1A1 mRNA |
CTD |
PMID:15849716 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Upf2 |
UPF2, regulator of nonsense mediated mRNA decay |
decreases expression |
EXP |
Clotrimazole results in decreased expression of UPF2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr17:72,224,575...72,335,896
Ensembl chr17:72,225,316...72,335,855
|
|
G |
Uqcr10 |
ubiquinol-cytochrome c reductase, complex III subunit X |
increases expression |
EXP |
Clotrimazole results in increased expression of UQCR10 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr14:79,566,151...79,569,017
Ensembl chr14:79,566,157...79,569,003
|
|
G |
Vash2 |
vasohibin 2 |
increases expression |
EXP |
Clotrimazole results in increased expression of VASH2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr13:102,529,718...102,561,204
Ensembl chr13:102,529,719...102,560,391
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases secretion |
ISO |
[Clotrimazole co-treated with Imatinib Mesylate] results in increased secretion of VEGFA protein Clotrimazole results in increased secretion of VEGFA protein |
CTD |
PMID:25863232 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wnt2 |
Wnt family member 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of WNT2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 4:46,328,408...46,374,673
Ensembl chr 4:46,333,998...46,374,402
|
|
G |
Xpo4 |
exportin 4 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of XPO4 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr15:31,717,016...31,807,723
Ensembl chr15:31,716,762...31,807,908
|
|
G |
Zbtb10 |
zinc finger and BTB domain containing 10 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ZBTB10 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515
|
|
G |
Zfp407 |
zinc finger protein 407 |
increases expression |
EXP |
Clotrimazole results in increased expression of ZFP407 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr18:77,571,140...77,970,282
Ensembl chr18:77,571,204...77,974,129
|
|
G |
Zscan2 |
zinc finger and SCAN domain containing 2 |
decreases expression |
EXP |
Clotrimazole results in decreased expression of ZSCAN2 mRNA |
CTD |
PMID:30047161 |
|
NCBI chr 1:134,833,701...134,848,957
Ensembl chr 1:134,833,871...134,848,952
|
|
|
G |
Adcy9 |
adenylate cyclase 9 |
increases activity |
ISO |
Econazole results in increased activity of ADCY9 protein |
CTD |
PMID:30607468 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression decreases activity |
ISO |
Econazole promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Econazole results in increased expression of CYP3A4 mRNA Econazole results in decreased activity of CYP3A4 protein |
CTD |
PMID:15135088 PMID:17998298 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases response to substance |
ISO |
CYP51A1 gene results in decreased susceptibility to Econazole |
CTD |
PMID:18694951 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Econazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Kcna3 |
potassium voltage-gated channel subfamily A member 3 |
multiple interactions decreases activity |
ISO |
[Econazole results in decreased activity of KCNA3 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 |
|
NCBI chr 2:194,632,106...194,634,059
Ensembl chr 2:194,632,196...194,650,138
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
ISO |
Econazole results in decreased activity of KCNH2 protein [Econazole results in decreased activity of KCNH2 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Econazole promotes the reaction [NR1I2 protein binds to NCOA1 protein] |
CTD |
PMID:17998298 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Econazole binds to and results in increased activity of NR1I2 protein; Econazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Econazole promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:17998298 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[tebuconazole co-treated with Econazole] results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:30698772 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
[tebuconazole co-treated with Econazole] results in increased phosphorylation of PRKAA2 protein |
CTD |
PMID:30698772 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Econazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
ISO |
[Econazole results in decreased activity of TRPM2 protein] inhibits the reaction [Mustard Gas results in increased abundance of Calcium] |
CTD |
PMID:22036725 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
[tebuconazole co-treated with Econazole] results in increased phosphorylation of ULK1 protein; dorsomorphin inhibits the reaction [[tebuconazole co-treated with Econazole] results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:30698772 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCB11 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCC2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression multiple interactions increases expression |
ISO EXP |
enilconazole results in decreased expression of ABCC3 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA enilconazole results in increased expression of ABCC3 mRNA |
CTD |
PMID:29451352 PMID:33426623 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCD3 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ACOX1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Adk |
adenosine kinase |
increases expression |
ISO |
enilconazole results in increased expression of ADK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression multiple interactions increases expression |
ISO EXP |
enilconazole results in decreased expression of ALDH1A1 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA enilconazole results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ALDH2 mRNA [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein |
CTD |
PMID:32201337 PMID:34830855 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Ano1 |
anoctamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ANO1 mRNA |
CTD |
PMID:29106682 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
enilconazole results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression affects binding |
ISO |
Dihydrotestosterone inhibits the reaction [enilconazole results in increased activity of AR protein]; enilconazole inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; enilconazole inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; enilconazole inhibits the reaction [Metribolone results in increased activity of AR protein] enilconazole results in decreased expression of AR mRNA enilconazole binds to AR protein |
CTD |
PMID:15064155 PMID:18324785 PMID:21310686 PMID:30853599 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression |
ISO |
enilconazole results in increased expression of ATP8B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Cat |
catalase |
increases expression |
ISO |
enilconazole results in increased expression of CAT mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
enilconazole results in increased expression of CCL5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions decreases expression |
ISO |
[enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein enilconazole results in decreased expression of CES2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects binding decreases expression |
ISO |
enilconazole binds to CFTR protein enilconazole results in decreased expression of CFTR mRNA; enilconazole results in decreased expression of CFTR protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
enilconazole results in increased expression of COMT protein |
CTD |
PMID:32201337 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression |
ISO |
enilconazole affects the expression of CYP11A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP17A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity affects secretion |
ISO |
enilconazole results in decreased activity of CYP19A1 protein enilconazole affects the secretion of CYP19A1 mRNA |
CTD |
PMID:10806373 PMID:15554355 PMID:26141389 PMID:30853599 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO |
enilconazole results in increased activity of CYP1A1 protein enilconazole results in increased expression of CYP1A1 mRNA; enilconazole results in increased expression of CYP1A1 protein enilconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:19070657 PMID:21762035 PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects expression multiple interactions |
ISO |
enilconazole affects the expression of CYP1A2 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of CYP1B1 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1B1 protein |
CTD |
PMID:32201337 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP27A1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
enilconazole results in increased expression of CYP2B2 mRNA [enilconazole co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression affects expression |
ISO |
[enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA enilconazole results in increased expression of CYP2B10 enilconazole affects the expression of CYP2B6 mRNA |
CTD |
PMID:27853109 PMID:32201337 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of CYP2C19 mRNA; enilconazole results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA enilconazole results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects expression decreases activity multiple interactions increases expression |
ISO |
enilconazole affects the expression of CYP3A4 mRNA enilconazole results in decreased activity of CYP3A4 protein [Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [enilconazole co-treated with methidathion] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA enilconazole results in increased expression of CYP3A4 protein |
CTD |
PMID:21762035 PMID:25028461 PMID:32201337 PMID:34273450 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[enilconazole co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA enilconazole results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of CYP3A5 mRNA; enilconazole results in increased expression of CYP3A5 protein [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein |
CTD |
PMID:32201337 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity |
ISO |
enilconazole results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
enilconazole results in decreased expression of CYP7A1 mRNA [enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA enilconazole results in decreased expression of CYP7A1 mRNA; enilconazole results in decreased expression of CYP7A1 protein |
CTD |
PMID:29451352 PMID:32194361 PMID:32201337 PMID:32814239 PMID:33426623 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP8B1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dnm1 |
dynamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of DNM1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538
|
|
G |
Eln |
elastin |
decreases expression multiple interactions |
EXP |
enilconazole results in decreased expression of ELN mRNA [enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
enilconazole binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ESR2 mRNA enilconazole binds to and results in increased activity of ESR2 protein |
CTD |
PMID:30853599 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of FABP6 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
enilconazole results in increased expression of FAS mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of FGF15 mRNA enilconazole results in increased expression of FGF15 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
enilconazole results in increased expression of GPX1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of GPX2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
enilconazole results in increased expression of GSR mRNA |
CTD |
PMID:29451352 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
decreases expression |
ISO |
enilconazole results in decreased expression of GSS mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein |
CTD |
PMID:34830855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Haao |
3-hydroxyanthranilate 3,4-dioxygenase |
decreases expression |
ISO |
enilconazole results in decreased expression of HAAO mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression |
ISO |
enilconazole affects the expression of HMGCR mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
affects expression |
ISO |
enilconazole affects the expression of HMGCS1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
decreases expression |
ISO |
enilconazole results in decreased expression of HSD17B13 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
enilconazole affects the expression of HSD3B1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
enilconazole results in increased expression of IFNG mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il17a |
interleukin 17A |
multiple interactions increases expression |
ISO |
enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] enilconazole results in increased expression of IL17A mRNA |
CTD |
PMID:22289359 PMID:32814239 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
enilconazole results in increased expression of IL1A mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
enilconazole results in increased expression of IL1B mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
enilconazole results in increased expression of IL6 mRNA |
CTD |
PMID:27393971 PMID:32201337 PMID:32814239 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
enilconazole results in increased expression of JUN mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khk |
ketohexokinase |
decreases expression |
ISO |
enilconazole results in decreased expression of KHK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Klf4 |
KLF transcription factor 4 |
affects expression decreases expression |
ISO |
enilconazole affects the expression of KLF4 mRNA enilconazole results in decreased expression of KLF4 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Ky |
kyphoscoliosis peptidase |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA enilconazole results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
enilconazole results in increased expression of LCN2 |
CTD |
PMID:27393971 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
enilconazole results in decreased expression of LHB protein |
CTD |
PMID:36410587 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
enilconazole results in increased expression of LPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Ly6d |
lymphocyte antigen 6 family member D |
decreases expression |
ISO |
enilconazole results in decreased expression of LY6D mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
enilconazole results in increased expression of MAPK8 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Megf11 |
multiple EGF-like-domains 11 |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA enilconazole results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:64,892,312...65,218,984
Ensembl chr 8:64,892,387...65,216,061
|
|
G |
Mep1b |
meprin A subunit beta |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MEP1B mRNA enilconazole results in decreased expression of MEP1B mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,365,289...12,392,840
|
|
G |
Mlxipl |
MLX interacting protein-like |
decreases expression |
ISO |
enilconazole results in decreased expression of MLXIPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions increases expression |
EXP |
[enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA enilconazole results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression |
ISO |
enilconazole results in decreased expression of MTTP mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc1 |
mucin 1, cell surface associated |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC1 mRNA enilconazole results in decreased expression of MUC1 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Muc17 |
mucin 17, cell surface associated |
decreases expression |
ISO |
enilconazole results in decreased expression of MUC17 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr12:19,527,251...19,536,924
Ensembl chr12:19,527,321...19,538,522
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC2 mRNA enilconazole results in decreased expression of MUC2 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions decreases expression |
ISO |
[clothianidin co-treated with enilconazole] results in decreased expression of NR0B2 mRNA enilconazole results in decreased expression of NR0B2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of NR1H4 mRNA enilconazole results in increased expression of NR1H4 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
[enilconazole co-treated with methidathion] results in increased activity of NR1I2 protein; enilconazole binds to and results in increased activity of NR1I2 protein; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] enilconazole results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 PMID:17438109 PMID:21115097 PMID:25028461 PMID:29973476 PMID:33049310 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions affects response to substance |
ISO |
enilconazole binds to and results in increased activity of NR1I3 protein; enilconazole inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein] NR1I3 protein affects the susceptibility to enilconazole |
CTD |
PMID:18832183 PMID:27853109 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
ISO |
enilconazole results in decreased expression of PDK4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
enilconazole binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
ISO |
enilconazole results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity |
ISO |
enilconazole results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarg |
retinoic acid receptor, gamma |
increases activity |
ISO |
enilconazole results in increased activity of RARG protein |
CTD |
PMID:20143881 |
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Retnlb |
resistin like beta |
affects expression |
ISO |
enilconazole affects the expression of RETNLB mRNA |
CTD |
PMID:29106682 |
|
NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
enilconazole results in increased expression of RGCC mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Rora |
RAR-related orphan receptor A |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of RORA protein |
CTD |
PMID:22289359 |
|
NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
enilconazole results in decreased expression of SCD mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
ISO |
enilconazole results in increased expression of SLC10A2 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC12A2 mRNA; enilconazole results in decreased expression of SLC12A2 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC22A5 mRNA; enilconazole results in decreased expression of SLC22A5 protein |
CTD |
PMID:36150497 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc26a3 |
solute carrier family 26 member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A3 mRNA; enilconazole results in decreased expression of SLC26A3 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
G |
Slc26a6 |
solute carrier family 26 member 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A6 mRNA; enilconazole results in decreased expression of SLC26A6 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 8:109,558,968...109,569,778
Ensembl chr 8:109,559,642...109,569,778
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
multiple interactions |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC9A3 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G |
Slco4a1 |
solute carrier organic anion transporter family, member 4a1 |
increases expression |
ISO |
enilconazole results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
enilconazole results in increased expression of SOD1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SOD2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects expression decreases expression |
ISO EXP |
enilconazole affects the expression of STAR mRNA enilconazole results in decreased expression of STAR mRNA |
CTD |
PMID:30853599 PMID:36410587 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SULT1B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases expression |
ISO |
enilconazole results in increased expression of SULT1C2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tff3 |
trefoil factor 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of TFF3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
enilconazole results in increased expression of TNF mRNA |
CTD |
PMID:27393971 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases expression |
ISO |
enilconazole results in decreased expression of UGT2B7 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
isoconazole results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
A2m |
alpha-2-macroglobulin |
decreases expression |
EXP |
Ketoconazole results in decreased expression of A2M mRNA |
CTD |
PMID:18289764 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aadat |
aminoadipate aminotransferase |
affects expression |
EXP |
Ketoconazole affects the expression of AADAT mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Aamp |
angio-associated, migratory cell protein |
increases expression |
ISO |
Ketoconazole results in increased expression of AAMP mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 9:75,863,382...75,869,188
Ensembl chr 9:75,863,389...75,868,547
|
|
G |
Aatf |
apoptosis antagonizing transcription factor |
decreases expression |
EXP |
Ketoconazole results in decreased expression of AATF mRNA |
CTD |
PMID:25787151 |
|
NCBI chr10:69,299,029...69,392,207
Ensembl chr10:69,299,037...69,392,201
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
increases expression |
EXP |
Ketoconazole results in increased expression of ABAT mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions decreases expression |
EXP |
Ketoconazole inhibits the reaction [Clofibrate results in increased expression of ABCA1 mRNA] Ketoconazole results in decreased expression of ABCA1 mRNA |
CTD |
PMID:14690017 PMID:37077353 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca3 |
ATP binding cassette subfamily A member 3 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ABCA3 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:13,382,439...13,439,748
Ensembl chr10:13,382,540...13,439,745
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
[Ketoconazole results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:20147439 PMID:20829430 PMID:23956101 PMID:24014644 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport decreases expression multiple interactions affects expression decreases activity |
ISO EXP |
ABCB1 protein results in increased transport of Ketoconazole Ketoconazole results in decreased expression of ABCB1A mRNA Ketoconazole inhibits the reaction [Genistein results in increased expression of ABCB1A mRNA] Ketoconazole affects the expression of ABCB1 mRNA Ketoconazole inhibits the reaction [ABCB1A protein results in increased secretion of fluorexon]; Ketoconazole inhibits the reaction [Pregnenolone Carbonitrile results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Pregnenolone Carbonitrile results in increased expression of ABCB1 protein] Ketoconazole results in decreased expression of ABCB1 mRNA Ketoconazole results in decreased activity of ABCB1 protein [Ketoconazole binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Ketoconazole results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; Ketoconazole binds to and results in decreased activity of ABCB1 protein; Ketoconazole inhibits the reaction [3,3'-diindolylmethane results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [ABCB1 protein affects the transport of Digoxin]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased chemical synthesis of globotriaosylceramide]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased chemical synthesis of Glucosylceramides]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased chemical synthesis of Lactosylceramides]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased secretion of fluorexon]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Ketoconazole inhibits the reaction [Doxorubicin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Ethanol results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Hydrogen Peroxide affects the expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Ketoconazole inhibits the reaction [Spironolactone results in increased expression of ABCB1 protein]; Ketoconazole inhibits the reaction [titanium dioxide results in increased expression of ABCB1 mRNA] |
CTD |
PMID:10350002 PMID:12235267 PMID:14662772 PMID:15969931 PMID:16819505 PMID:17365992 PMID:18355885 PMID:19070657 PMID:20624464 PMID:21459122 PMID:23707768 PMID:23976943 PMID:25542144 PMID:25844889 PMID:32185415 PMID:33766574 PMID:35478211 PMID:36653537 PMID:36893891 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity multiple interactions |
ISO EXP |
Ketoconazole results in decreased activity of ABCB4 protein [Chenodeoxycholic Acid co-treated with Ketoconazole] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28437613 PMID:30985903 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [titanium dioxide results in increased expression of ABCC1 mRNA] |
CTD |
PMID:33766574 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity multiple interactions |
ISO EXP |
Ketoconazole results in decreased activity of ABCC2 protein Ketoconazole inhibits the reaction [Spironolactone results in increased expression of ABCC2 mRNA] |
CTD |
PMID:19070657 PMID:19766108 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of ABCD2 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases expression |
EXP |
Ketoconazole inhibits the reaction [Genistein results in increased expression of ABCG2 mRNA] Ketoconazole results in increased expression of ABCG2 mRNA |
CTD |
PMID:32185415 PMID:37077353 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abracl |
ABRA C-terminal like |
decreases expression |
ISO |
Ketoconazole results in decreased expression of ABRACL mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 1:12,654,951...12,665,143
Ensembl chr 1:12,654,838...12,665,207
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
increases expression |
EXP |
Ketoconazole results in increased expression of ACAA1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of ACAA2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
increases expression |
EXP |
Ketoconazole results in increased expression of ACADL mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
increases expression |
EXP |
Ketoconazole results in increased expression of ACADM mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
increases expression |
EXP |
Ketoconazole results in increased expression of ACADS mRNA |
CTD |
PMID:37077353 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
ISO |
Ketoconazole results in increased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
increases expression |
EXP |
Ketoconazole results in increased expression of ACOT8 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ACSL4 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
increases expression |
EXP |
Ketoconazole results in increased expression of ACSL5 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ACSM1 mRNA |
CTD |
PMID:28263823 |
|
NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
affects expression |
EXP |
Ketoconazole affects the expression of ADAM9 mRNA |
CTD |
PMID:25787151 |
|
NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917
|
|
G |
Adcy6 |
adenylate cyclase 6 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ADCY6 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ADH1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adi1 |
acireductone dioxygenase 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of ADI1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP |
Ketoconazole results in increased expression of ADIPOQ mRNA |
CTD |
PMID:36653537 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adora1 |
adenosine A1 receptor |
increases expression |
EXP |
Ketoconazole results in increased expression of ADORA1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of ADRB2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Aebp2 |
AE binding protein 2 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of AEBP2 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 4:173,527,881...173,566,033
Ensembl chr 4:173,528,344...173,593,100
|
|
G |
Agps |
alkylglycerone phosphate synthase |
increases expression |
ISO |
Ketoconazole results in increased expression of AGPS mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830
|
|
G |
Agrp |
agouti related neuropeptide |
decreases expression |
EXP |
Ketoconazole results in decreased expression of AGRP mRNA |
CTD |
PMID:37077353 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Agt |
angiotensinogen |
increases expression |
EXP |
Ketoconazole results in increased expression of AGT mRNA |
CTD |
PMID:37077353 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases expression increases activity |
ISO EXP |
AHR promotes the reaction [Ketoconazole results in increased expression of NQO1 mRNA]; AHR promotes the reaction [Ketoconazole results in increased expression of NQO1 protein]; Ketoconazole inhibits the reaction [Phenobarbital results in increased expression of AHR protein] Ketoconazole results in increased expression of AHR mRNA Ketoconazole results in increased activity of AHR protein [Ketoconazole results in increased activity of AHR protein] which results in increased activity of and results in increased localization of NFE2L2 protein; [Ketoconazole results in increased activity of and results in increased localization of AHR protein] which results in increased expression of CYP1A1 mRNA; [Ketoconazole results in increased activity of and results in increased localization of AHR protein] which results in increased expression of CYP1A1 protein; AHR protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; AHR protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]]; Ketoconazole results in increased activity of and results in increased localization of AHR protein Ketoconazole inhibits the reaction [Phenobarbital results in increased expression of AHR mRNA]; Ketoconazole inhibits the reaction [Phenobarbital results in increased expression of AHR protein]; Ketoconazole inhibits the reaction [Phenytoin results in increased expression of AHR protein] |
CTD |
PMID:17505019 PMID:17923278 PMID:21753779 PMID:25000292 PMID:31168027 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions increases expression |
EXP |
[Ketoconazole co-treated with Carbon Tetrachloride] results in increased expression of AHRR mRNA Ketoconazole results in increased expression of AHRR mRNA |
CTD |
PMID:31168027 |
|
NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
increases expression |
EXP |
Ketoconazole results in increased expression of AHSG mRNA |
CTD |
PMID:36653537 |
|
NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of AKAP12 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
EXP |
Ketoconazole results in increased expression of AKR1B7 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Akr1c15 |
aldo-keto reductase family 1, member C15 |
increases expression |
EXP |
Ketoconazole results in increased expression of AKR1C15 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr17:66,181,493...66,208,090
Ensembl chr17:66,181,493...66,208,061
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of ALAS1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alb |
albumin |
affects expression |
EXP |
Ketoconazole affects the expression of ALB mRNA |
CTD |
PMID:36653537 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects expression |
EXP |
Ketoconazole affects the expression of ALDH1A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Alkbh7 |
alkB homolog 7 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ALKBH7 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression |
ISO |
Ketoconazole inhibits the reaction [Calcifediol results in increased expression of ALPL mRNA] Ketoconazole results in increased expression of ALPL protein |
CTD |
PMID:21542014 PMID:31099283 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Amdhd1 |
amidohydrolase domain containing 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of AMDHD1 mRNA |
CTD |
PMID:31099283 |
|
NCBI chr 7:28,043,923...28,059,156
Ensembl chr 7:28,043,716...28,059,156
|
|
G |
Amh |
anti-Mullerian hormone |
increases expression |
ISO |
Ketoconazole results in increased expression of AMH protein |
CTD |
PMID:16684832 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Ang |
angiogenin |
increases expression |
ISO |
Ketoconazole results in increased expression of ANG mRNA |
CTD |
PMID:36621641 |
|
NCBI chr15:24,312,711...24,323,361
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of ANXA1 mRNA |
CTD |
PMID:25787151 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of AOX1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Ap3m1 |
adaptor related protein complex 3 subunit mu 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of AP3M1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr15:3,246,616...3,264,846
Ensembl chr15:3,246,926...3,264,844
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of APAF1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
EXP |
Ketoconazole results in increased expression of APOA1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects expression |
EXP |
Ketoconazole affects the expression of APOA4 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
EXP |
Ketoconazole results in increased expression of APOE mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression increases activity decreases activity |
ISO EXP |
[Goserelin co-treated with Dutasteride co-treated with bicalutamide co-treated with Ketoconazole] results in decreased expression of AR protein; Ketoconazole inhibits the reaction [Metribolone results in increased activity of AR protein]; Ketoconazole inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein] Ketoconazole inhibits the reaction [Phenytoin results in increased expression of AR protein] Ketoconazole results in decreased expression of AR protein Ketoconazole results in increased activity of AR protein Ketoconazole results in decreased activity of AR protein |
CTD |
PMID:11118046 PMID:18324785 PMID:19226368 PMID:19587329 PMID:24323034 PMID:26867867 PMID:29162470 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of ARG1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Asb17 |
ankyrin repeat and SOCS box-containing 17 |
increases expression |
ISO |
Ketoconazole results in increased expression of ASB17 mRNA |
CTD |
PMID:31099283 |
|
NCBI chr 2:242,775,887...242,786,950
Ensembl chr 2:242,775,994...242,786,903
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Ketoconazole results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of ASS1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
increases expression |
ISO |
Ketoconazole results in increased expression of ATAD2 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:12164941 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atp5mc2 |
ATP synthase membrane subunit c locus 2 |
increases expression |
ISO |
Ketoconazole results in increased expression of ATP5MC2 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 7:133,791,341...133,799,713
Ensembl chr 7:133,791,342...133,799,733
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
increases expression |
EXP |
Ketoconazole results in increased expression of ATP5PO mRNA |
CTD |
PMID:37077353 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Atp6v1d |
ATPase H+ transporting V1 subunit D |
increases expression |
EXP |
Ketoconazole results in increased expression of ATP6V1D mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 6:97,656,725...97,672,295
Ensembl chr 6:97,656,576...97,672,303
|
|
G |
Avp |
arginine vasopressin |
increases expression |
EXP |
Ketoconazole results in increased expression of AVP mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bace1 |
beta-secretase 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of BACE1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
EXP |
Ketoconazole results in increased expression of BAD mRNA |
CTD |
PMID:25787151 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Ketoconazole inhibits the reaction [Calcifediol results in decreased expression of BAX mRNA] |
CTD |
PMID:21542014 PMID:31629065 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; Ketoconazole inhibits the reaction [Calcifediol results in increased expression of BCL2 mRNA] |
CTD |
PMID:21542014 PMID:31629065 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
Ketoconazole results in increased expression of BCL2L11 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Becn1 |
beclin 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of BECN1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
affects expression |
EXP |
Ketoconazole affects the expression of BHMT mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bicc1 |
BicC family RNA binding protein 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of BICC1 mRNA |
CTD |
PMID:31099283 |
|
NCBI chr20:17,449,639...17,686,775
Ensembl chr20:17,449,560...17,686,776
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
Ketoconazole results in increased expression of BID mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bin1 |
bridging integrator 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of BIN1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
EXP |
Ketoconazole results in increased expression of BIRC5 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]]; Ketoconazole inhibits the reaction [Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA]] |
CTD |
PMID:31843813 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of BMP4 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Ketoconazole results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bnc1 |
basonuclin zinc finger protein 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of BNC1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 1:135,917,676...135,943,333
Ensembl chr 1:135,917,687...135,943,333
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
ISO |
Ketoconazole results in increased expression of BNIP1 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157
|
|
G |
Bnip2 |
BCL2 interacting protein 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of BNIP2 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Ketoconazole results in increased expression of BNIP3 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
decreases expression |
ISO |
Ketoconazole results in decreased expression of BNIP3L mRNA |
CTD |
PMID:36621641 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
C10h5orf15 |
similar to human chromosome 5 open reading frame 15 |
increases expression |
ISO |
Ketoconazole results in increased expression of C5ORF15 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr10:36,563,989...36,576,593
Ensembl chr10:36,563,958...36,576,590
|
|
G |
C1galt1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of C1GALT1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831
|
|
G |
C1galt1c1 |
C1GALT1-specific chaperone 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of C1GALT1C1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787
|
|
G |
C3 |
complement C3 |
increases expression |
EXP |
Ketoconazole results in increased expression of C3 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C5h1orf174 |
similar to human chromosome 1 open reading frame 174 |
increases expression |
ISO |
Ketoconazole results in increased expression of C1ORF174 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 5:164,515,578...164,520,022
Ensembl chr 5:164,515,559...164,520,021
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CACNA1H mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CACNA1I mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d3 |
calcium voltage-gated channel auxiliary subunit alpha2delta 3 |
increases expression |
EXP |
Ketoconazole results in increased expression of CACNA2D3 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
|
|
G |
Cacna2d4 |
calcium voltage-gated channel auxiliary subunit alpha2delta 4 |
increases expression |
EXP |
Ketoconazole results in increased expression of CACNA2D4 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 4:152,408,588...152,521,478
Ensembl chr 4:152,408,657...152,521,268
|
|
G |
Cacnb1 |
calcium voltage-gated channel auxiliary subunit beta 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CACNB1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:82,998,182...83,018,838
Ensembl chr10:82,998,182...83,018,694
|
|
G |
Cacng3 |
calcium voltage-gated channel auxiliary subunit gamma 3 |
increases expression |
EXP |
Ketoconazole results in increased expression of CACNG3 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 1:177,201,361...177,297,019
Ensembl chr 1:177,201,288...177,297,024
|
|
G |
Cacng4 |
calcium voltage-gated channel auxiliary subunit gamma 4 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CACNG4 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:92,683,778...92,745,842
Ensembl chr10:92,683,761...92,746,126
|
|
G |
Calb1 |
calbindin 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CALB1 mRNA |
CTD |
PMID:31099283 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calb2 |
calbindin 2 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CALB2 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of CAP1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of CA2 mRNA; Ketoconazole results in increased expression of CAR2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Carmil1 |
capping protein regulator and myosin 1 linker 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CARMIL1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr17:40,807,921...41,088,326
Ensembl chr17:40,808,389...41,088,326
|
|
G |
Casp12 |
caspase 12 |
increases expression |
ISO |
Ketoconazole results in increased expression of CASP12 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Ketoconazole results in increased activity of CASP3 protein Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Ketoconazole results in increased activity of CASP3 protein] |
CTD |
PMID:17936189 PMID:19631732 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
decreases expression increases expression |
EXP |
Ketoconazole results in decreased expression of CASP6 mRNA Ketoconazole results in increased expression of CASP6 mRNA |
CTD |
PMID:25787151 PMID:25808816 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
increases expression |
EXP |
Ketoconazole results in increased expression of CASP7 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
affects expression |
ISO |
Ketoconazole affects the expression of CASP8AP2 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Ketoconazole results in increased expression of CASP9 mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CAT mRNA |
CTD |
PMID:25787151 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
Ketoconazole results in increased expression of CAV1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbx7 |
chromobox 7 |
increases expression |
EXP |
Ketoconazole results in increased expression of CBX7 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
|
|
G |
Ccdc8 |
coiled-coil domain containing 8 |
increases expression |
EXP |
Ketoconazole results in increased expression of CCDC8 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 1:77,679,521...77,682,849
Ensembl chr 1:77,679,218...77,683,090
|
|
G |
Cck |
cholecystokinin |
increases expression |
EXP |
Ketoconazole results in increased expression of CCK mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; PTGER2 protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; PTGER3 protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]] Ketoconazole results in increased expression of CCL2 mRNA |
CTD |
PMID:16784723 PMID:37077353 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
multiple interactions |
ISO |
Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]; Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]; PTGER2 protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; PTGER3 protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]] |
CTD |
PMID:16784723 |
|
NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO EXP |
Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; PTGER2 protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; PTGER3 protein promotes the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]] Ketoconazole results in increased expression of CCL5 mRNA |
CTD |
PMID:16784723 PMID:23688403 PMID:37077353 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression affects expression |
ISO EXP |
Ketoconazole results in increased expression of CCN1 mRNA Ketoconazole affects the expression of CCN1 mRNA |
CTD |
PMID:36621641 PMID:36653537 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
Ketoconazole results in increased expression of CCNG1 mRNA |
CTD |
PMID:18289764 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd200 |
Cd200 molecule |
increases expression |
ISO |
Ketoconazole results in increased expression of CD200 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd247 |
Cd247 molecule |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased abundance of Calcitriol]; Ketoconazole inhibits the reaction [Calcifediol promotes the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased expression of VDR protein]] |
CTD |
PMID:24792400 |
|
NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263
|
|
G |
Cd274 |
CD274 molecule |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CD274 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased abundance of Calcitriol]; Ketoconazole inhibits the reaction [Calcifediol promotes the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased expression of VDR protein]] |
CTD |
PMID:24792400 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd3d |
CD3 delta subunit of T-cell receptor complex |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased abundance of Calcitriol]; Ketoconazole inhibits the reaction [Calcifediol promotes the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased expression of VDR protein]] |
CTD |
PMID:24792400 |
|
NCBI chr 8:45,287,803...45,293,342
Ensembl chr 8:45,288,749...45,301,809
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased abundance of Calcitriol]; Ketoconazole inhibits the reaction [Calcifediol promotes the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased expression of VDR protein]] |
CTD |
PMID:24792400 |
|
NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased abundance of Calcitriol]; Ketoconazole inhibits the reaction [Calcifediol promotes the reaction [[[CD3G protein binds to CD3D protein binds to CD3E protein binds to CD247 protein] which co-treated with CD28 protein] results in increased expression of VDR protein]] |
CTD |
PMID:24792400 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cd47 |
Cd47 molecule |
increases expression |
ISO |
Ketoconazole results in increased expression of CD47 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CDC42EP2 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
increases expression |
EXP |
Ketoconazole results in increased expression of CDC42EP3 mRNA |
CTD |
PMID:28263823 |
|
NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CDK2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CDK6 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO EXP |
Ketoconazole results in increased expression of CDKN1A mRNA |
CTD |
PMID:16483768 PMID:25808816 PMID:37077353 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Ketoconazole results in increased expression of CDKN1B mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
affects expression |
EXP |
Ketoconazole affects the expression of CDKN2C mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
EXP |
Ketoconazole results in increased expression of CEBPA mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cenpu |
centromere protein U |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CENPU mRNA |
CTD |
PMID:36621641 |
|
NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823
|
|
G |
Cep15 |
centrosomal protein 15 |
increases expression |
ISO |
Ketoconazole results in increased expression of CEP15 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838
|
|
G |
Cep19 |
centrosomal protein 19 |
increases expression |
ISO |
Ketoconazole results in increased expression of CEP19 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr11:68,677,869...68,687,117
Ensembl chr11:68,677,871...68,687,022
|
|
G |
Ces2h |
carboxylesterase 2H |
affects expression |
EXP |
Ketoconazole affects the expression of CES2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cfb |
complement factor B |
increases expression |
EXP |
Ketoconazole results in increased expression of CFB mRNA |
CTD |
PMID:36653537 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CGA mRNA |
CTD |
PMID:25808816 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chrac1 |
chromatin accessibility complex subunit 1 |
increases expression |
ISO |
Ketoconazole results in increased expression of CHRAC1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 7:105,013,047...105,016,435
Ensembl chr 7:105,013,015...105,017,136
|
|
G |
Cibar1 |
CBY1 interacting BAR domain containing 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CIBAR1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 5:25,613,993...25,632,440
Ensembl chr 5:25,614,033...25,632,489
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
EXP |
Ketoconazole results in increased expression of CIDEA mRNA |
CTD |
PMID:36653537 PMID:37077353 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Ckap2l |
cytoskeleton associated protein 2-like |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CKAP2L mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
ISO |
Ketoconazole results in increased expression of CLCF1 mRNA |
CTD |
PMID:31099283 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
increases expression |
ISO |
Ketoconazole results in increased expression of CLEC4E mRNA |
CTD |
PMID:31099283 |
|
NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767
|
|
G |
Clmn |
calmin |
multiple interactions |
ISO |
Ketoconazole promotes the reaction [Calcitriol results in increased expression of CLMN mRNA] |
CTD |
PMID:26485663 |
|
NCBI chr 6:123,707,710...123,807,283
Ensembl chr 6:123,713,507...123,807,272
|
|
G |
Cln5 |
CLN5, intracellular trafficking protein |
affects expression |
ISO |
Ketoconazole affects the expression of CLN5 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr15:79,893,573...79,903,438
Ensembl chr15:79,893,548...79,903,438 Ensembl chr 2:79,893,548...79,903,438
|
|
G |
Clu |
clusterin |
affects expression decreases expression |
EXP |
Ketoconazole affects the expression of CLU mRNA Ketoconazole results in decreased expression of CLU mRNA |
CTD |
PMID:17558187 PMID:18289764 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
affects expression |
EXP |
Ketoconazole affects the expression of CMTM6 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 8:114,422,934...114,441,034
Ensembl chr 8:114,422,921...114,441,033
|
|
G |
Cmtm7 |
CKLF-like MARVEL transmembrane domain containing 7 |
increases expression |
ISO |
Ketoconazole results in increased expression of CMTM7 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 8:114,448,037...114,474,958
Ensembl chr 8:114,448,042...114,474,621
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CNR2 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
Ketoconazole results in decreased expression of COL1A1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Commd2 |
COMM domain containing 2 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of COMMD2 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 2:141,848,661...141,852,907
Ensembl chr 2:141,848,680...141,852,888
|
|
G |
Cop1 |
COP1, E3 ubiquitin ligase |
decreases expression |
ISO |
Ketoconazole results in decreased expression of COP1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr13:71,467,164...71,561,826
Ensembl chr13:71,429,961...71,538,890
|
|
G |
Copz1 |
COPI coat complex subunit zeta 1 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of COPZ1 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr 7:134,409,523...134,435,661
Ensembl chr 7:134,409,799...134,435,662
|
|
G |
Cox18 |
cytochrome c oxidase assembly factor COX18 |
affects expression |
ISO |
Ketoconazole affects the expression of COX18 mRNA |
CTD |
PMID:36621641 |
|
NCBI chr14:17,864,581...17,877,483
Ensembl chr14:17,865,857...17,877,480
|
|
G |
Cpn2 |
carboxypeptidase N subunit 2 |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CPN2 mRNA |
CTD |
PMID:31099283 |
|
NCBI chr11:70,486,054...70,495,937
Ensembl chr11:70,486,057...70,496,472
|
|
G |
Cpped1 |
calcineurin-like phosphoesterase domain containing 1 |
affects expression |
EXP |
Ketoconazole affects the expression of CPPED1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr10:3,701,522...3,821,050
Ensembl chr10:3,701,459...3,821,054
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CPT1B mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of CPT2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cr2 |
complement C3d receptor 2 |
increases expression |
EXP |
Ketoconazole results in increased expression of CR2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases expression |
ISO EXP |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein] Ketoconazole results in decreased expression of CREB1 mRNA Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein]; Ketoconazole inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12164941 PMID:17680988 PMID:37077353 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crem |
cAMP responsive element modulator |
affects expression decreases expression |
EXP |
Ketoconazole affects the expression of CREM mRNA Ketoconazole results in decreased expression of CREM mRNA |
CTD |
PMID:18355885 PMID:36653537 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CRHR2 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Crls1 |
cardiolipin synthase 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of CRLS1 mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 3:120,119,822...120,138,674
Ensembl chr 3:120,119,852...120,138,655
|
|
G |
Crym |
crystallin, mu |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CRYM mRNA |
CTD |
PMID:36653537 |
|
NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
EXP |
Ketoconazole results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsl |
cathepsin L |
decreases expression |
ISO |
Ketoconazole results in decreased expression of CTSL mRNA |
CTD |
PMID:36621641 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
affects expression |
EXP |
Ketoconazole affects the expression of CTSS mRNA |
CTD |
PMID:18289764 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [Biological Products results in increased expression of CXCL10 mRNA]; Ketoconazole inhibits the reaction [Biological Products results in increased expression of CXCL10 protein] |
CTD |
PMID:24471457 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
increases expression |
EXP |
Ketoconazole results in increased expression of CXCL14 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
increases expression |
EXP |
Ketoconazole results in increased expression of CYBA mRNA |
CTD |
PMID:37077353 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
decreases expression increases expression |
EXP |
Ketoconazole results in decreased expression of CYCS mRNA Ketoconazole results in increased expression of CYCS mRNA |
CTD |
PMID:25787151 PMID:37077353 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyct |
cytochrome c, testis |
increases expression |
EXP |
Ketoconazole results in increased expression of CYCT mRNA |
CTD |
PMID:25787151 |
|
NCBI chr 3:61,290,090...61,297,158
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of CYP11A1 mRNA |
CTD |
PMID:26610754 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions decreases activity |
ISO |
Ketoconazole binds to and results in decreased activity of CYP11B1 protein Ketoconazole results in decreased activity of CYP11B1 protein |
CTD |
PMID:15743198 PMID:31982514 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases activity multiple interactions increases expression |
ISO |
Ketoconazole results in decreased activity of CYP11B2 protein Ketoconazole binds to and results in decreased activity of CYP11B2 protein; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA] Ketoconazole results in increased expression of CYP11B2 mRNA |
CTD |
PMID:15743198 PMID:16935330 PMID:31982514 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity decreases expression multiple interactions |
ISO EXP |
Ketoconazole results in decreased activity of CYP17A1 protein Ketoconazole results in decreased expression of CYP17A1 mRNA Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:11118046 PMID:15743198 PMID:15771425 PMID:15934942 PMID:16935330 PMID:25993309 PMID:31330226 PMID:31982514 PMID:36653537 More...
|
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity decreases expression multiple interactions decreases activity |
ISO EXP |
Ketoconazole results in increased activity of CYP19A1 protein Ketoconazole results in decreased expression of CYP19A1 mRNA [Ketoconazole results in increased activity of CYP19A1 protein] which results in increased chemical synthesis of Estrone; [Ketoconazole results in increased activity of CYP19A1 protein] which results in increased metabolism of Androstenedione Ketoconazole results in decreased activity of CYP19A1 protein |
CTD |
PMID:20087668 PMID:27159630 PMID:31330226 PMID:36374910 PMID:36653537 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions decreases activity |
ISO EXP |
Ketoconazole results in increased activity of CYP1A1 protein Ketoconazole results in increased expression of CYP1A1 mRNA Ketoconazole binds to and results in decreased activity of and results in increased expression of CYP1A1 protein; Ketoconazole results in increased expression of and results in increased activity of CYP1A1 protein Ketoconazole results in increased expression of CYP1A1 mRNA; Ketoconazole results in increased expression of CYP1A1 protein Ketoconazole results in decreased activity of CYP1A1 protein [Ketoconazole results in increased activity of and results in increased localization of AHR protein] which results in increased expression of CYP1A1 mRNA; [Ketoconazole results in increased activity of and results in increased localization of AHR protein] which results in increased expression of CYP1A1 protein; Dactinomycin inhibits the reaction [Ketoconazole results in increased expression of CYP1A1 mRNA]; Ketoconazole binds to and results in decreased activity of and results in increased expression of CYP1A1 protein; Ketoconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Ketoconazole results in increased expression of and results in increased activity of CYP1A1 protein [Ketoconazole co-treated with Carbon Tetrachloride] results in increased expression of CYP1A1 mRNA; Ketoconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:14709627 PMID:17283379 PMID:18420780 PMID:18493746 PMID:19070657 PMID:21753779 PMID:25000292 PMID:26886340 PMID:31168027 PMID:34181028 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression decreases activity |
ISO EXP |
Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [CYP1A2 protein results in increased metabolism of Triazines] Ketoconazole results in increased expression of CYP1A2 mRNA; Ketoconazole results in increased expression of CYP1A2 protein Ketoconazole results in decreased activity of CYP1A2 protein Ketoconazole inhibits the reaction [CYP1A2 protein results in increased metabolism of 3-cyano-7-ethoxycoumarin] Ketoconazole inhibits the reaction [CYP1A2 protein results in increased oxidation of Uroporphyrinogens] |
CTD |
PMID:1567206 PMID:9305587 PMID:12814958 PMID:15618748 PMID:15879494 PMID:15916432 PMID:18420780 PMID:19858067 PMID:24120545 PMID:25000292 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Ketoconazole results in decreased activity of CYP1B1 protein |
CTD |
PMID:14709627 PMID:18420780 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
EXP ISO |
[Ketoconazole co-treated with Calcitriol] results in increased expression of CYP24A1 mRNA; Ketoconazole inhibits the reaction [Calcitriol results in increased activity of CYP24A1 protein] Ketoconazole inhibits the reaction [Calcifediol results in increased expression of CYP24A1 mRNA]; Ketoconazole promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] [Ketoconazole results in decreased metabolism of alfacalcidol] which results in decreased expression of CYP24A1 mRNA; [Ketoconazole results in decreased metabolism of Calcitriol] which results in increased expression of CYP24A1 mRNA; Ketoconazole promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] Ketoconazole results in decreased activity of CYP24A1 protein |
CTD |
PMID:16483768 PMID:16824767 PMID:18840526 PMID:20206692 PMID:26485663 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases response to substance increases expression decreases activity multiple interactions |
ISO EXP |
Ketoconazole results in decreased susceptibility to CYP26A1 protein Ketoconazole results in increased expression of CYP26A1 mRNA Ketoconazole results in decreased activity of CYP26A1; Ketoconazole results in decreased activity of CYP26A1 protein [[Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased metabolism of Tretinoin] which results in decreased chemical synthesis of 4-hydroxyretinoic acid; [[Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased metabolism of Tretinoin] which results in decreased chemical synthesis of 4-oxoretinoic acid; [Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased chemical synthesis of 4-hydroxyretinoic acid; [Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased chemical synthesis of 4-oxoretinoic acid; [Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased metabolism of Tretinoin; Ketoconazole inhibits the reaction [CYP26A1 mRNA results in increased chemical synthesis of 4-hydroxyretinoic acid]; Ketoconazole inhibits the reaction [CYP26A1 mRNA results in increased chemical synthesis of 4-oxoretinoic acid]; Ketoconazole inhibits the reaction [CYP26A1 mRNA results in increased metabolism of 4-oxoretinoic acid]; Ketoconazole inhibits the reaction [CYP26A1 mRNA results in increased metabolism of Tretinoin]; Ketoconazole inhibits the reaction [CYP26A1 protein inhibits the reaction [Tretinoin results in increased activity of FAS protein]]; Ketoconazole inhibits the reaction [CYP26A1 protein inhibits the reaction [Tretinoin results in increased activity of TNF protein]]; Ketoconazole inhibits the reaction [CYP26A1 protein inhibits the reaction [Tretinoin results in increased activity of TNFSF10 protein]]; Ketoconazole inhibits the reaction [CYP26A1 protein results in increased metabolism of and results in decreased susceptibility to Tretinoin]; Ketoconazole inhibits the reaction [CYP26A1 protein results in increased metabolism of Tretinoin]; Ketoconazole inhibits the reaction [CYP26A1 results in increased metabolism of Tretinoin] |
CTD |
PMID:12091498 PMID:14532297 PMID:15703382 PMID:18059332 PMID:21906690 PMID:25492813 PMID:28263823 PMID:37077353 More...
|
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions decreases activity |
ISO |
Ketoconazole inhibits the reaction [CYP26B1 protein results in increased metabolism of Tretinoin]; Ketoconazole inhibits the reaction [CYP26B1 results in increased metabolism of Tretinoin] Ketoconazole results in decreased activity of CYP26B1 |
CTD |
PMID:14532297 PMID:21906690 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp26c1 |
cytochrome P450, family 26, subfamily C, polypeptide 1 |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [CYP26C1 protein results in increased metabolism of alitretinoin]; Ketoconazole inhibits the reaction [CYP26C1 protein results in increased metabolism of Tretinoin] |
CTD |
PMID:21906690 |
|
NCBI chr 1:235,458,961...235,468,433
Ensembl chr 1:235,459,356...235,466,842
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
decreases activity |
EXP |
Ketoconazole results in decreased activity of CYP27B1 protein |
CTD |
PMID:16483768 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
affects expression decreases activity increases expression |
EXP |
Ketoconazole affects the expression of CYP2A1 mRNA Ketoconazole results in decreased activity of CYP2A1 protein Ketoconazole results in increased expression of CYP2A1 protein |
CTD |
PMID:7986207 PMID:15879494 PMID:18355885 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Ketoconazole inhibits the reaction [CYP2A2 protein results in increased metabolism of 7-benzyloxyquinoline] |
CTD |
PMID:19858067 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Ketoconazole results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
Ketoconazole inhibits the reaction [CYP2B1 protein results in increased metabolism of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
affects expression |
EXP |
Ketoconazole affects the expression of CYP2B15 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity increases expression multiple interactions |
ISO |
Ketoconazole results in decreased activity of CYP2B6 protein Ketoconazole results in decreased activity of CYP2B10 protein Ketoconazole results in increased expression of CYP2B10 mRNA Ketoconazole inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:14709627 PMID:16608920 PMID:17438109 PMID:17966066 PMID:18420780 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions decreases activity |
EXP |
Ketoconazole inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] Ketoconazole results in decreased activity of CYP2C11 protein |
CTD |
PMID:15879494 PMID:19858067 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions decreases activity |
EXP ISO |
Ketoconazole inhibits the reaction [CYP2C6 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin] Ketoconazole results in decreased activity of CYP2C29 protein Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] Ketoconazole results in decreased activity of CYP2C19 protein Ketoconazole results in decreased activity of CYP2C6 protein |
CTD |
PMID:12814958 PMID:14709627 PMID:15618748 PMID:15879494 PMID:18420780 PMID:19858067 PMID:24120545 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity multiple interactions |
ISO |
Ketoconazole results in decreased activity of CYP2C8 protein Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:14709627 PMID:15601807 PMID:24120545 |
|
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
Ketoconazole inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases expression decreases activity |
ISO |
Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [CYP2D6 protein results in increased metabolism of YM 758] Ketoconazole results in decreased expression of CYP2D22 mRNA; Ketoconazole results in decreased expression of CYP2D22 protein Ketoconazole results in decreased activity of CYP2D22 protein; Ketoconazole results in decreased activity of CYP2D6 protein Ketoconazole inhibits the reaction [CYP2D22 protein results in increased metabolism of Dextromethorphan]; Ketoconazole inhibits the reaction [Maneb results in decreased expression of CYP2D22 protein]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]]; Ketoconazole inhibits the reaction [Nicotine results in increased expression of CYP2D22 mRNA]; Ketoconazole inhibits the reaction [Nicotine results in increased expression of CYP2D22 protein]; Ketoconazole inhibits the reaction [Paraquat results in decreased expression of CYP2D22 protein]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]; Nicotine inhibits the reaction [Ketoconazole results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [Ketoconazole results in decreased expression of CYP2D22 protein] |
CTD |
PMID:15618748 PMID:16595712 PMID:18420780 PMID:19230594 PMID:19594327 PMID:22334051 PMID:24120545 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Ketoconazole results in decreased activity of CYP2E1 protein |
CTD |
PMID:15618748 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases activity |
ISO |
Ketoconazole results in decreased activity of CYP2J2 protein |
CTD |
PMID:12851038 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases expression increases response to substance decreases activity increases expression increases metabolic processing |
EXP ISO |
Ketoconazole inhibits the reaction [CYP3A2 protein results in increased metabolism of 7-benzyloxyquinoline]; Ketoconazole inhibits the reaction [Phenytoin results in increased expression of CYP3A2 protein] Ketoconazole results in decreased expression of CYP3A4 mRNA; Ketoconazole results in decreased expression of CYP3A4 protein CYP3A4 protein results in increased susceptibility to Ketoconazole Ketoconazole results in decreased activity of CYP3A2 protein; Ketoconazole results in decreased activity of CYP3A4 protein Ketoconazole results in increased expression of CYP3A4 mRNA CYP3A4 protein results in increased metabolism of Ketoconazole [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 1-hydroxymethylmidazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased degradation of vanoxerine; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased hydroxylation of Midazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased metabolism of Midazolam; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased metabolism of Testosterone; [Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased metabolism of Triazolam; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole affects the reaction [CYP3A4 polymorphism affects the metabolism of cabozantinib]; Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of acalabrutinib]; Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of vandetanib]; Ketoconazole binds to and results in decreased activity of CYP3A4 protein; Ketoconazole inhibits the reaction [3,3'-diindolylmethane results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [[Amiodarone co-treated with CYP3A4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[Amiodarone co-treated with CYP3A4 protein] results in increased expression of TNF mRNA]; Ketoconazole inhibits the reaction [[CYP3A4 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac]; Ketoconazole inhibits the reaction [[CYP3A4 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 5-hydroxydiclofenac]; Ketoconazole inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of Hydroxytestosterones]; Ketoconazole inhibits the reaction [[desethylamiodarone co-treated with CYP3A4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[desethylamiodarone co-treated with CYP3A4 protein] results in increased expression of TNF mRNA]; Ketoconazole inhibits the reaction [Calcitriol results in increased expression of CYP3A4 protein]; Ketoconazole inhibits the reaction [Corticosterone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Corticosterone results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [CYP3A4 protein affects the metabolism of Endosulfan]; Ketoconazole inhibits the reaction [CYP3A4 protein affects the metabolism of Mefloquine]; Ketoconazole inhibits the reaction [CYP3A4 protein promotes the reaction [Oxygen deficiency results in increased expression of EPO mRNA]]; Ketoconazole inhibits the reaction [CYP3A4 protein promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]]; Ketoconazole inhibits the reaction [CYP3A4 protein results in decreased abundance of Midazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in decreased methylation of adinazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in decreased methylation of mono-N-demethyladinazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in decreased susceptibility to Docetaxel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased abundance of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 11,12-epoxy-5,8,14-eicosatrienoic acid]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 3'-p-hydroxypaclitaxel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of clozapine N-oxide]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of norclozapine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased degradation of Clopidogrel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased degradation of Ticlopidine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased glutathionylation of dauricine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydrolysis of Testosterone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Carbofuran]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Metoprolol]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of mono-N-desethylamiodarone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of nefazodone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Nifedipine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of 8-epidiosbulbin E acetate]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of and results in decreased abundance of Quetiapine Fumarate]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Arachidonic Acid]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of bufalin]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of bufogenin]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of cabozantinib]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of carbosulfan]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of cinobufagin]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of eldecalcitol]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Felodipine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of laquinimod]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Terfenadine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Testosterone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Triazolam]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of YM 758]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 2-oxo-clopidogrel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of dimemorfan]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of Lithocholic Acid]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of Nifedipine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of Paclitaxel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Clopidogrel]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Endosulfan]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Ticlopidine]; Ketoconazole inhibits the reaction [erdafitinib results in decreased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of CYP3A4 protein]; Ketoconazole inhibits the reaction [Phenobarbital results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Ketoconazole inhibits the reaction [U 0126 affects the activity of CYP3A4 protein]; Ketoconazole results in increased expression of and results in decreased activity of CYP3A4 protein |
CTD |
PMID:9600717 PMID:10952769 PMID:10997946 PMID:11377097 PMID:11502731 PMID:12072427 PMID:12237780 PMID:12569440 PMID:12675279 PMID:12695342 PMID:12814958 PMID:15005856 PMID:15135088 PMID:15279827 PMID:15306208 PMID:15328084 PMID:15466163 PMID:15557344 PMID:15560889 PMID:15618748 PMID:15731592 PMID:15764719 PMID:15784650 PMID:15860655 PMID:15869686 PMID:15879494 PMID:15896247 PMID:15969931 PMID:16012074 PMID:16146350 PMID:16204965 PMID:16207822 PMID:16390352 PMID:16608920 PMID:16819505 PMID:16855053 PMID:17438109 PMID:17702393 PMID:17998298 PMID:18799805 PMID:18809730 PMID:18846481 PMID:19226368 PMID:19230594 PMID:19299527 PMID:19328226 PMID:19358519 PMID:19593786 PMID:19812348 PMID:19858067 PMID:20233841 PMID:20307514 PMID:20507880 PMID:20863320 PMID:21336516 PMID:21349323 PMID:21402137 PMID:21566342 PMID:21915887 PMID:22178124 PMID:22447115 PMID:22651985 PMID:22785256 PMID:23146034 PMID:23274770 PMID:23707768 PMID:23850985 PMID:23876819 PMID:24120545 PMID:24246759 PMID:24799337 PMID:24819614 PMID:25343516 PMID:25542144 PMID:26038696 PMID:26286065 PMID:26718876 PMID:27485346 PMID:27871908 PMID:28119166 PMID:28238727 PMID:28887089 PMID:29782822 PMID:30087611 PMID:31102695 PMID:31293154 PMID:31629065 PMID:31870919 PMID:33253783 PMID:33438235 PMID:33775687 PMID:34153224 PMID:34189909 PMID:34648813 PMID:34780725 PMID:36332690 PMID:36893891 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions decreases activity affects expression |
EXP |
[Strychnine co-treated with Ketoconazole] results in decreased expression of CYP3A23-3A1 protein; Ketoconazole inhibits the reaction [CYP3A23-3A1 protein results in increased metabolism of 7-benzyloxyquinoline]; Ketoconazole inhibits the reaction [Genistein results in increased expression of CYP3A23-3A1 mRNA] Ketoconazole results in decreased activity of CYP3A23-3A1 protein Ketoconazole affects the expression of CYP3A23-3A1 mRNA |
CTD |
PMID:12814958 PMID:15879494 PMID:18355885 PMID:19858067 PMID:32185415 PMID:35358606 More...
|
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions affects response to substance decreases activity |
ISO |
CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus]; Ketoconazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [CYP3A5 protein affects the metabolism of Alfentanil]; Ketoconazole inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone]; Ketoconazole inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]; Ketoconazole inhibits the reaction [erdafitinib results in decreased activity of CYP3A5 protein]; Ketoconazole inhibits the reaction [flunisolide results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Fluticasone results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Triamcinolone Acetonide results in increased expression of CYP3A5 mRNA] CYP3A5 gene polymorphism affects the susceptibility to Ketoconazole Ketoconazole results in decreased activity of CYP3A5 protein |
CTD |
PMID:15557344 PMID:15731592 PMID:19384264 PMID:24555085 PMID:26302866 PMID:31102695 PMID:34189909 PMID:37788138 More...
|
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
increases expression |
EXP |
Ketoconazole results in increased expression of CYP4B1 mRNA |
CTD |
PMID:37077353 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
decreases activity |
ISO |
Ketoconazole results in decreased activity of CYP4F12 protein |
CTD |
PMID:14709627 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
affects expression |
EXP |
Ketoconazole affects the expression of CYP4F2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:11,717,208...11,733,507
Ensembl chr 7:11,717,208...11,733,506
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity increases expression decreases response to substance multiple interactions increases activity |
ISO EXP |
Ketoconazole results in decreased activity of CYP51A1 protein Ketoconazole results in increased expression of CYP51 mRNA CYP51A1 gene results in decreased susceptibility to Ketoconazole [Ketoconazole results in increased activity of CYP51 protein] which results in increased abundance of Lanosterol CYP51A1 gene inhibits the reaction [Ketoconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Ketoconazole results in decreased metabolism of and results in increased abundance of 14-methylergosta-8,24(28)-dien-3,6-diol]; CYP51A1 gene inhibits the reaction [Ketoconazole results in decreased metabolism of and results in increased abundance of Lanosterol] Ketoconazole results in increased expression of CYP51 mRNA; Ketoconazole results in increased expression of CYP51 protein |
CTD |
| |